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The introduction of nanoformulated antiretroviral therapeutic regimens is a promising 
alternative to standard once a day oral treatment of HIV infection. Our lab has pioneered 
this effort and was successful in harnessing mononuclear phagocytes (monocytes, 
dendritic cells and macrophages) as nanoformulated drug carriers. The approach was 
developed as Trojan horses for drug transport, delivery and distribution to sites of viral 
replication in order to facilitate microbial elimination in HIV sanctuaries. However, the 
remaining challenges for current antiretroviral nanoformulations include to formulate a 
broad range of hydrophilic short-acting drugs, and to elucidate the mechanism of 
sequestered nanoparticles in macrophages at the subcellular level. To this end, we 
developed a two-step synthesis to create a long-acting lamivudine (2’,3’-dideoxy-3’-
thiacytidine, 3TC).  A stable hydrophobic pro-drug crystal formulation was produced by 
poloxamer drug encasement. Conversion of the hydrophilic 3TC significantly extended 
its bioavailability facilitated by chemical drug conjugation to a fatty acid and creating a 
myristoylated drug. A folate targeted poloxamer 407 coated a newly formed 
nanocrystalline pro-drug markedly improving cell uptake, bioavailability and 
pharmacokinetic profiles. Reduced cytotoxicity and robust antiretroviral activities were 
also achieved. The nanoparticle interactions at the subcellular level were investigated 
vial nanoformulated protease inhibitor. Quantitative SWATH-MS proteomics for complete 
 III 
recording of fragment ion peptide precursors in biological sample. and cell profiling were 
applied for endolysosomal trafficking for HIV-1 assembly and nanoformulation depot 
formation. We believe these findings unveil new opportunities for nanoformulated 
antiretroviral therapy and have brought the idea of long-acting antiretroviral therapy 
closer to the clinical translation. 
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1.1. HIV and AIDS 
1.1.1. Epidemic 
Human immunodeficiency virus infection and acquired immune deficiency 
syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human 
immunodeficiency virus. Since its first discovery in 1981, HIV/AIDS has killed more than 
25 million people worldwide. It has become a global pandemic. As of 2014, 
approximately 36.9 million people are living with HIV globally, and 1.18 million people 
died of HIV/AIDS. Due to the widespread infection of HIV there has been a 
determination for the discovery and use of medicinal agents that can inhibit the virus. 
HIV type-1 (HIV-1) displays extraordinary genetic variation and can be phylogenetically 
classified into three distinct groups and several subgroups across the globe. While HIV-1 
clade C dominates the HIV-1 epidemic worldwide with more than 50% of the total viral 
infections, predominantly in Southern Africa, and other parts of Asia, HIV-1 subtype B is 
mainly found in Europe and America with about 10% of the total infections [1, 2]. 
1.1.2. Pathobiology 
HIV is a member of the genus Lentivirus, belonging to the family Retrovirus. HIV is 
roughly spherical with a diameter of about 80 to 120 nm in diameter. It is transmitted as 
single-stranded, positive-sense, enveloped RNA virus. It is composed of 2,000 copies of 
the viral protein p24, which is tightly bound to nucleocapsid proteins and enzymes 
including reverse transcriptase, proteases, ribonuclease and integrase. The p24 protein 
is coated by capsid, which helps in ready adsorption onto the host cell surface and 
provides a protective shell for the nucleic acid core.  A series of host cell proteins and 
viral specific glycoproteins including gp41 and gp120 are embedded in the phospholipid 
 3 
bilayer. In addition to the viral core HIV has six regulatory genes (tat, rev, nef, vif, vpr 
and vpu) that affect its abilities to infect, replicate and assemble within the cell [3, 4]. 
HIV primarily infects components of the human immune system such as CD4+ T 
cells, monocytes, macrophages, glial cells, and dendritic cells. The HIV virion enters 
host cells by the adsorption of glycoproteins on its surface to receptors on the target cell 
followed by fusion of the viral envelope with the cell membranes and the release of the 
HIV capsid into the cell. Entry to the cell begins through interaction of the trimeric 
envelope gp160 spike with both CD4 and a chemokine receptor, either CXCR4 or 
CCR5. The virus will first attach to the host cell via the CD4 receptor through the CD4 
binding domains of gp120. The envelope complex undergoes a structural change, 
exposing the chemokine binding domains of gp120 and allowing them to interact with the 
target chemokine receptor. Fusion peptide gp41 then can penetrate the cell membrane, 
causing the collapse of the extracellular portion of gp41 into a hairpin, fusion of the host 
cell membranes as well as subsequent entry of the viral capsid.  The HIV RNA and 
various enzymes are injected into the cell. The viral single-strand RNA genome is 
transcribed into double-strand DNA and integrated into a host chromosome. Infection 
and ultimate destruction of CD4+ T cells heralds secondary immune deficiency and 
concomitant co-morbid conditions that include opportunistic infections and primary virus-
induced metabolic changes that affect also the function of the central nervous system 
(CNS), gut and lymphoid tissues. Within days after primary infection HIV invades the 
nervous system through lymphocytes and macrophages that cross the blood brain 
barrier (BBB) and serve as Trojan Horses for viral dissemination [4, 5]. 
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1.2. Macrophages and HIV reservoir  
Mononuclear phagocyte including blood monocyte, tissue macrophages and 
dendritic cells are principal cells involved in the clearance and inactivation of the HIV. 
These cells act as the reservoirs and vehicles for the dissemination of this viral 
pathogen. After binding and uptake, the ability of HIV-1 to complete its replication cycle 
depends mainly on differentiation and activation of its target cell and on molecular 
determinants of the infecting viral strain. The viral infection is highly dependent on the 
state of macrophage differentiation and the role of macrophages is a reservoir for 
persistent lentiviral infection.  It will decide whether viral infection is abortive, restricted, 
permissive, latent, or enhanced. Cellular differentiation parallels macrophage 
susceptibility to viral infection. The viral life cycle in monocytes and macrophages is 
regulated by physiological factors involved in differentiation from monocyte precursors to 
mature tissue macrophages [6-8]. 
The transmission of HIV occurs through exchange of body fluids and is mediated in 
large measure by cell-associated virus. HIV-1 in leukocytes of seminal and vaginal 
fluids, uterine cervix, and gastrointestinal lamina propria support a cell-mediated 
transmission of virus. After primary viral exposure, high levels of HIV replication ensue in 
the infected human host, which results in plasma viremia. Virus seeds tissue 
macrophages and continues to replicate during the long subclinical latency period. Viral 
replication is regulated by humoral and cellular immune factors. These viral-mediated 
immune regulatory factors are produced against a number of HIV gene products. 
Macrophage amplify production of a variety of immunoregulatory molecules such as 
complement, arachidonic acid metabolites, neutral proteases, various growth factors, 
and other cytokines including platelet-derived growth factor, tumor necrosis factor α 
(TNF- α), colony-stimulating factors (CSFs), the interleukins, and the interferons (IFN- α 
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and IFN-β). Many cytokines like interleukins (IL-1, -3, -4, and -6), macrophage and 
granulocyte-macrophage CSFs (M-CSF and GM-CSF), and TNF- α up-regulate HIV 
gene expression and thus play important roles in disease onset and progression. Some 
cytokines like IFN-α, -β, and –γ and IL-4 exert suppressive effects on HIV replication. 
The cytokine responses to viral infection complement immune-specific antiviral 
responses including antibody-dependent complement-mediated, neutralization, and cell-
mediated immune responses. 
Viral reservoir sites protect the virus from biological elimination pathways, immune 
response, and antiretroviral drugs. They allow viral dissemination throughout the body, 
and serve as a major source of viral rebound upon treatment failure, and contribute to 
the development of drug resistance. Resting CD4+ cells are known to be the main 
cellular reservoir for the latent HIV-1 infection due to their ability to persist for a long 
span.  Although the pool of latently infected, resting CD4+ T cells has been the most 
extensively studied HIV reservoir to date and is widely recognized as one of the major 
obstacles to achieving eradication of virus, low levels of HIV replication may persist in 
infected individuals. The lack of consensus on the life span of the latent viral reservoir 
has sparked an intense debate regarding the possibility that low levels of HIV replication 
in subsets of CD4+ T cells in the lymphoid tissue may contribute to replenishment of 
infected CD4+ T cells. By this mechanism, the overall half-life of the viral reservoir could 
be indefinitely extended. In this regard, previous mathematical models have suggested 
that productively infected CD4+ T cells have a relatively short in-vivo half-life (<1 day) 
following initiation of ART. The data indicate that such cells should no longer be present 
in infected individuals who had been receiving clinically effective ART for extended 
periods. However, activated CD4+ T cells, enriched at high purity from the blood of a 
viremic individual receiving ART, carry HIV proviral DNA and are capable of 
spontaneously producing virions in culture. Furthermore, phylogenetic analyses of HIV 
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env provided evidence for virologic cross-talk between infected resting and activated 
CD4+ T cells in the absence of detectable plasma viremia. HIV replicates primarily in the 
lymphoid tissues with extremely high levels of viral replication and extensive destruction 
of CD4+ T cells in the gut-associated lymphoid tissue (GLAT) of infected animals or 
humans. The overall HIV burden is substantially higher in the GALT than in the blood of 
infected individuals receiving long-term treatment [9]. 
Besides, other cellular reservoirs including monocytes and macrophages are the 
most important reservoirs outside the blood stream, which have been described to play 
an important role in HIV persistence. Monocytes and macrophages are relatively long-
lived cells since HIV has very low cytopathic effects on them, making them a persistent 
reservoir of HIV regardless of the presence of highly active antiretroviral therapy. 
Monocytes and macrophages express efflux transporters, which contribute to maintain 
subtherapeutic concentrations of antiretroviral medications in these cells and may 
explain why macrophages are sanctuaries for HIV. Macrophages are a major and crucial 
target of HIV-1 infection and, as potential long-term HIV reservoirs, infected cells must 
be selectively destroyed to achieve HIV-1 eradication. As macrophages function as 
potent antigen-presenting cells and mediators of both innate and acquired immunity, 
HIV-1-mediated macrophage deficiency is catastrophic to the global immune response. 
A significant obstacle in clearing virus from infected individuals is multiple latently 
infected viral sanctuaries. Latent HIV-1 can emerge with recrudescence as a productive 
infection later in disease progression and might also represent a source for the 
emergence of resistant HIV-1. Many regimens eventually fail, primarily because of lack 
of adherence to strict regimens, delayed toxicities and/or the emergence of drug-
resistant HIV strains. 
The function of macrophages in vivo presents a long-lived target for HIV-1 
infection; the half-life (t1/2) of macrophages is significantly longer than that of an activated 
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lymphocyte (weeks/years versus hours/days). More specifically, the life span of activated 
HIV-1-infected lymphocytes is relatively attenuated, with a t1/2 of approximately 0.8–1.1 
days, whereas productively infected macrophages maintain viability and virus production 
for at least 30 days. The latter study represents an in vitro assay and, although studies 
observing the t1/2 of HIV-1 infected macrophages in vivo are lacking, existing studies 
define a distinct advantage for macrophages when observing their life span and virus 
production over time. Viral dynamics in vivo indicate that CCR5-using viruses 
predominate early during infection. As macrophages display high CCR5 expression 
levels, they represent an early target for the establishment of both chronic and latent 
infection. Macrophages interact with lymphocytes during antigen presentation, conferring 
direct infection to new CD4+ T lymphocytic targets. Macrophages have also been 
implicated as the causative agent in central nervous system (CNS) infection of HIV-1, 
which often manifests itself as HIV-associated dementia during the later stages in the 
progression to AIDS [9, 10].  
Macrophages represent a crucial target for establishment and maintenance of 
chronic and latent HIV-1 infection. Various macrophage-like cells, including dendritic 
cells, alveolar macrophages, monocyte precursors and microglial cells, contribute to the 
complex interplay between systemic infection and administration of ART. Macrophages 
are found in every organ system and tissue, and, because of high CCR5 expression, 
represent a target for early establishment and maintenance of latent viral reservoirs.  
1.3. Traditional antiretroviral therapies 
The introduction of highly active antiretroviral therapy started from 1996, which has 
been a great medical success in terms of increasing survival and improving the quality of 
life of the HIV-infected patient population. Due to the steady advancements in HIV 
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research and drug discovery, HIV infected patients on current combination antiretroviral 
therapy (cART) can effectively maintain undetectable plasma virus levels for years. As 
the threat of HIV/AIDS persists to rise, effective drug treatments are required to treat the 
infected people. Antiretroviral therapy has markedly reduced HIV/AIDS related deaths 
and opportunistic infectious diseases. This has resulted in prolonged survival of 
individuals infected with HIV. Long-term medical care has significantly improved the 
patients’ life expectancy and quality by suppression of plasma viral replication. Viral 
resistance to antiretroviral (ARV) drugs can be addressed with two or more drug 
combinations that target two to more drug targets within the same or different viral 
proteins. The drugs available for the treatment of HIV/AIDS are proven to be selective 
and effective with an acceptable safety to suppress plasma viral propagation. Alternate 
drug combinations will be utilized if drug resistant virus appears in clinics. 
As the mechanisms and proteins essential for HIV replication are characterized, 
most of these viral proteins have been used as drug targets for inhibiting HIV replication. 
Potent inhibitors of viral entry, replications, intergration and maturation have been 
developed as therapeutic agents. These drugs are generally referred to as entry 
(CCR5/CD4), reverse transcriptase, integrase and protease inhibitors, respectively. 
Reverse transcriptase inhibitors have been elucidated in detail, which revealed two 
distinct classes of molecules that inhibit enzyme activity through unique mechanism. In 
combination, these reverse transcriptase inhibitors greatly reduce the risk of inducing 
drug-resistant virus. Nowadays, there are 26 or more drugs available for the treatment of 
HIV in the USA. Since single agent ART is no longer clinically relevant, the clinical use of 
combinations of drugs is more efficacious compared with HIV monotherapy. Clinically, 
therapeutic regimens often target multiple checkpoints in viral replication such as the 
combination of protease inhibitors with reverse transcriptase inhibitors. The development 
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of these agents for cART has been effective at suppressing plasma viral load and 
preventing drug resistance [11].  
The efficacy of ART cellular pharmacology in macrophages has significant 
implications in disease progression. The interplay between ART cellular pharmacology in 
macrophages directly affects viral loads, selection of resistance mutations both within 
and between subsets of HIV-1 target cells, eradication of systemic virus and long-term 
patient survival. Eradication of systemic HIV-1 infection is not possible without clearance 
of latently infected cells. As macrophages are a sentinel target for HIV-1 infection and 
latency, understanding the cellular pharmacology of current antiretroviral therapy in 
macrophages is essential. 
1.3.1. Entry inhibitors 
Entry inhibitors inhibit entry of HIV-1 into host cells and there are two anti-HIV 
drugs approved by the US Federal Drug Administration (FDA): enfuvirtide and 
maraviroc. Enfuvirtide is a peptide derived from a repeat sequence of the 
transmembrane portion of HIV-1 envelope, gp41, and inhibits the hairpin formation 
necessary for virus-host cell fusion to occur. Enfuvirtide sensitivity was largely 
independent of the coreceptor usage, and its overall antiviral activity in macrophages 
correlated more closely with HIV-1 entry by CCR5 rather than with entry through 
CXCR4. It is demonstrated the downstream effects of enfuvirtide relative to CXCR4- 
versus CCR5-mediated signaling and provide a foundation for understanding the effect 
of entry inhibitors on multiple cellular events in macrophages. Maraviroc is a small 
molecule, which inhibits viral entry by binding to the CCR5 coreceptor and inhibiting the 
receptor-coreceptor viral entry interaction required for HIV-1 entry into the host cell. The 
median effective concentration (EC50) for maraviroc in primary macrophages is reported 
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to be 0.5 nM for a subtype B M-R5 virus versus 0.2–2.9 nM in activated lymphocytes for 
R5-using viruses across multiple subtypes [12-14]. 
1.3.2. Nucleoside reverse transcriptase inhibitors  
Nucleoside reverse transcriptase inhibitors (NRTIs) have a well-established 
regulatory pathway and distinct clinical advantages. They are low plasma protein 
binding, sustained antiviral response and relative ease of chemical manufacture. There 
are about eight FDA approved NRTIs: zidovudine, didanosine, zalcitabine, stavudine, 
abacavir sulfate, lamivudine, entricitabine, and tonofovir disoproxil fumarate. The target 
of NRTIs in HIV-1 infection is the reversed transcriptase (RT), which is active early in the 
viral replication cycle. RT converts the genetic information of the virus stored at RNA into 
DNA by reverse transcription, which is a process necessary for continued viral 
replication. NRTIs are chiral small molecules that mimic natural nucleotides and require 
intracellular phosphyorylation to become functionally active against HIV-1 RT. In the 
triphosphate form, NRTIs compete with one of the four naturally occurring dNTP, 
namely, dCTP, dTTP, dATP or dGTP, for binding and DNA chain elongation near the 
active site of HIV-1 RT. As most NRTIs lack a 3′-hydroxyl terminus, incorporation of the 
analogue into the growing DNA strand results in termination of the DNA strand and the 
next phosphodiester bond is not formed. Because of these factors, both the 
concentration of cellular triphosphorylated drug and the levels of cellular dNTP pools 
play a key role in the efficacy of the NRTIs. Macrophages primarily remain in a resting 
G1 state and undergo limited DNA synthesis. Cellular dNTP levels are significantly lower 
in macrophages compared with activated cells. The EC50 for NRTIs ranges from 3 to 
300 nM in macrophages for acute infection. By contrast, the EC50 is larger than 25 µM 
in chronically infected macrophages. The differences indicate that chronic HIV-1 
infection alters the cellular milieu in a manner that modulates the ability of NRTI to 
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successfully become functionally active or subsequently inhibit viral reverse transcription 
[15, 16]. 
1.3.3. Non-nucleoside reverse transcriptase inhibitors  
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) make antiretroviral 
efficacy through interaction with binding pockets of HIV-1 RT and inhibiting its enzymatic 
activity by causing conformational changes at or near the active site. NNRTIs approved 
by FDA include etravirine, delavirdine, efavirenz and nevirapine. Although the cellular 
dNTP pool does not directly affect the mechanism of action of NNRTIs, the EC50 differs 
significantly for NNRTI against acute versus chronic infection in macrophages. The 
EC50 for inhibition of acute HIV-1 infection in macrophages ranges from 10 to 50 nM 
depending on the NNRTI; however, NNRTIs are not effective at inhibiting HIV-1 
replication in chronically infected macrophages. To date, the mechanism responsible for 
ineffective inhibition of viral replication in macrophages by NNRTI is incompletely 
understood. If this mechanism were solely responsible for differential activity of NNRTI in 
chronically activated macrophages, significant antiviral activity would probably still be 
observed because establishment of new infection and subsequent p24 production would 
be terminated. Intracellular accumulation of NNRTI within macrophages might present 
with a significantly diminished intracellular bioavailability profile relative to lymphocytes, 
which could present a direct link between differential activities of NNRTI in macrophages 
versus lymphocytes [17]. 
1.3.4. Protease inhibitors  
The HIV-1 protease is a member of the aspartic acid protease family and is 
structurally related to host aspartic acid proteases including renin, cathepsin D, gastrin, 
and pepsin. HIV-1 protease is a homodimer, composed of two noncovalently associated, 
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structurally identical polyprotein chains. The HIV genome is composed of three major 
genes including gag, pol and env. Transcription and translation of the gag and pol 
regions of the virus genome resultin the production of two large precursor polyproteins, 
p55 (gag) and a ribosomal frameshift product p160 (gag-pol). The enzyme active site 
contains well-defined subsites in which inhibitor or substrate side chains participate in 
tight binding interactions. HIV protease-mediated processing of the precursor 
polyproteins p55 and p160 occurs at different cleavage sites. Phe-Pro, Phe-Leu, and 
Phe-Thr are some of the scissile bonds, which can be used in the design of protease 
inhibitors. Protease inhibitors (PIs) have the ability to inhibit HIV-1 replication through 
competition for binding in the active site with the natural substrate. PIs can effectively 
inactivate the enzyme since it is not easily cleaved. Protease inhibitors are peptide-like 
chemicals that competitively inhibit the action of the virus aspatyl protease. They can 
affect the proteolytic cleavage of the polypeptide precursors into mature enzymes and 
structural proteins catalyzed by HIV protease. They can prevent proteolytic cleavage of 
HIV Gag and Pol polyproteins that include essential structural and enzymatic 
components of the virus, which prevents the conversion of HIV particles into their mature 
infectious form [18].  
The widely used PIs with FDA approval are amprenavir, tipranavir, indinavir, 
saquinavir, lopinavir, ritonavir, darunavir, atazanavir, and nelfinavir. PIs display potent 
activity in both acutely and chronically infected macrophages. The EC50 in acutely 
infected macrophages ranged from 10 to 120 nM, whereas the EC50 in chronically 
infected macrophages ranged from 400 to 3.3×103 nM. Higher rates of viral RNA 
metabolism in macrophages is considered as a mechanism responsible for higher EC50 
in macrophages. Plasma pharmacokinetics in vivo demonstrate inhibitory quotient 
values that are similar to the EC50 of PI in vitro for inhibition of chronic HIV-1 infection in 
macrophages. Macrophages are unique because they can be found in every tissue 
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compartment and organ systemically. Therefore, it is reasonable to suggest that many 
macrophages in vivo might be exposed to significantly lower levels of drug than those 
observed at inhibitory quotients in plasma in the circulating periphery [19]. 
1.3.5. Integrase inhibitors  
Integrase inhibitors act to inhibit integration of HIV-1 proviral genome into host cell 
DNA. HIV-1 integrase presents a highly selective target for anti-HIV therapeutics. 
Raltegravir is a novel representative integrase inhibitor approved by FDA. Raltegravir 
targets integrase, an HIV enzyme that integrates the viral genetic material into human 
chromosomes, a critical step in the pathogenesis of HIV and is metabolized away via 
glucuronidation, which has exhibited potent and durable antiretroviral activity [20]. 
1.3.6. Other potential therapeutics 
The elimination of virus cannot occur by a single mechanism, thus many new 
targets, including small interfering RNAs (siRNAs), carbohydrate-binding agents (CBAs), 
PI3K/Akt pathway inhibitors, and immunotoxins, are explored. The siRNAs could be 
useful for the induction of potent gene silencing by degradation of cognate RNA. The 
use of siRNA for HIV-1 infection presents a unique challenge because systemic or 
directed silencing of CXCR4 co-receptor would result in mortality, and silencing of CCR5 
co-receptor could represent a selective pressure for emergence of highly pathogenic 
CXCR4-using virus. CBAs target the heavily glycosylated HIV-1 envelope, impairing the 
ability of macrophages or dendritic cells to recognize and perform antigen presentation 
to CD4+ T-lymphocytes, subsequently impairing transfer infection. The mechanism of 
CBAs is predominantly extracellular, which makes them efficacious when co-
administered with other classes of drugs. The PI3K/Akt pathway is a cell survival 
pathway that is activated upon apoptotic stress and functions to activate downstream 
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modulators of cell survival. PI3K/Akt inhibitors were demonstrated to inhibit HIV-1 
replication in acutely infected primary macrophages, and their antiviral activity was only 
observed when drugs were co-administered with a compound that positively modulates 
nitric oxide-induced cytotoxicity in HIV-1 infection. Immunotoxins might provide a 
mechanism for targeted elimination of HIV-1-infected cells, and both novel design of 
immunotoxin-based antiviral agents and their effect on macrophages remains an 
ongoing area of research. Inhibitors targeting HIV-1 accessory proteins provide a 
targeted approach for elimination of HIV-1 within infected cells. Vpu provides an 
attractive target because interference with Vpu acts post-integration to confer abnormal 
packaging of newly formed virions [21]. 
Even though combination antiretroviral therapy (cART) provides stable viral 
suppression, it is still not perfect due to the undesirable side effects, especially for 
people undergoing long-term treatment. Besides, the traditional therapies find their 
limitations in multidrug resistance, lack of viral replication-targeted therapy. Traditional 
therapy is not able to eradicate HIV from infected individuals. During the early stages of 
HIV infection, HIV establishes reservoirs within cells where HIV lies latent, and tissues, 
which are inaccessible to optimal levels of antiviral drugs, thus escaping the action of 
antiretroviral drugs. Therefore, eliminating or preventing viral infection in macrophages is 
a key element to achieve viral eradication, and new strategies to enhance penetration of 
antiviral therapeutics in macrophages are urgently needed. Eradication of systemic HIV-
1 infection is not possible without clearance of latently infected cells. For these reasons, 
understanding dynamics of ART pharmacology in macrophages and subsequently 
eliminating productive infection in these cells, is critical to eliminating systemic HIV-1 
infection. 
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1.4. Novel nanomedicine for antiretroviral therapy 
Nanomedicine is one promising approach to target HIV in virus reservoir sites. Due 
to the introduction of highly active antiretroviral therapy (HAART) as well as the impact of 
preventive measures, the prevalence and incidence of HIV have declined globally over 
the last decade except for parts of Eastern Europe and Central Asia where a slight 
increase has been observed.  However, although potent compounds have been 
developed to suppress virus replication into undetectable levels in the blood of HIV 
infected patients, it is still a challenge to completely cure patients from HIV/AIDS.  
Therefore, there is an urgent need to investigate the residual viral source, virologic and 
physiologic mechanisms that allow viral persistence, in order to develop targeted drug 
delivery strategies to eliminate residual virus in HIV infected patients. 
To realize long-acting therapy, sustained dosage forms have had an extensive 
history and proven record of contribution to improve patient compliance. Formulation 
research and investigation has become indispensable in improving patients’ life quality. 
For chronic treatments, converting multiple daily doses to once-a-day dosing with 
sustained release dosage form has shown light to enhance patient compliance. The 
application of nanoformulations has been proven to be an important area of 
pharmaceutical research and development. 
Nanoparticles or nanomedicine refer to drug carrier particles and complexes in the 
range of 10-1000 nm. Nanoformulations include nanocrystals, colloids, nanoparticles, 
lipid vesicles, liposomes, biopolymers, and protein aggregates. These nanoformulations 
are intended to improve pharmaceutical properties and drug response by improving drug 
solubility, stability, biodistribution, pharmacokinetics, safety and efficacy. 
Nanotechnology-based drug delivery systems could potentially enhance cellular 
uptake of antiretroviral drugs into HIV host and infected cells in vitro and improve the 
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pharmacokinetics, pharmacodynamics and biodistribution of ARV agents in various 
rodent models. It should be noted that most of these reports are in early stage and use 
only a single agent formulation, which is no longer acceptable clinical practice for HIV 
therapy. The potential of nanotechonology to modify tissue distribution and extend 
plasma half-life of HIV drugs was demonstrated. When the antiretroviral drug is 
encapsulated into a nanosystem, its absorption, metabolism and excretion is not 
exclusively governed by drug properties; rather, the nanosystem’s physical-chemical 
properties, particularly surface-exposed molecules and electric charge, and size could 
modify the sustaining time and metabolic and elimination rates. Most current 
nanomedicine platforms for HIV treatment focus on drug delivery in the blood and on 
improving pharmacokinetic profiles. To reduce off-target effects and improve on-target 
drug distribution into tissues and cells that mediate or are linked to a clinical syndrome, 
an innovative nanoformulation must be stable both in vitro and in vivo for sufficient 
duration and exhibit physiochemical properties that allow distribution and localization of 
drug particles within the sites of interest, while minimizing peripheral toxicities [22, 23]. 
1.4.1. Polymeric nanoparticles 
Polymeric nanoparticles have shown great potentials in HIV therapy since 
polymers are versatile and can be customized to allow for encapsulation and controlled 
release of therapeutic agents from the nanoparticles. They can also realize reservoir 
targeting through decoration with ligands that bind to receptors on the target site. 
Peptides, proteins and antibodies are most widely used targeting ligands, which have 
shown to promote binding and uptake of nanoparticles encapsulating the drugs. 
Biodegradable polymers, like polyethylene glycol-block-polylactide (PEG-PLA), 
polymethylmethacrylate (PMMA), and methylmethacrylate-sulfopropylmethacrylate 
(MMA-SPM), have been applied to encapsulate antiretroviral drugs. Polymeric 
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nanoparticle with small particle sizes were found to improve drug loading efficiency and 
uptake. Modification of the polymers with ligands that target receptors expressed at the 
surface of endothelial cells has greatly improved antiretroviral efficacy. This delivery 
system can also enhance drug encapsulation and subsequent intracellular delivery in 
macrophages [22, 23]. 
1.4.2. Micelles 
Micelles are self-assembled colloidal systems consisting of amphiphilic molecules 
that spontaneously aggregate into particles at a concentration beyond the critical micelle 
concentration (CMC). A typical micelle has hydrophilic heads forming a shell structure, 
and the inner core structure serves as a reservoir for poorly water-soluble drugs. They 
have advantages including relatively small sizes (10-100 nm), ease of preparation, and 
prolonged in vivo circulation, which enable them to cross all kinds of physiological 
barriers. The application of Pluronic® copolymers inhibits efflux trasnporters, like P-
glycoprotein (Pgp) and Multidrug Resistance Protein (MRP), consequently facilitate drug 
delivery of substrates. Pluronic® block copolymers contains one hydrophobic 
poly(propylene oxide) (PPO) as the core, and two hydrophilic poly(ethylene oxide) (PEO) 
termini. Using polarized monolayers of bovine endothelial cells, Batrakova et al. 
examined the influence of Pluronic® block copolymers on the permeability of drugs, 
including Pgp substrates, organic anion transporter substrates, and compounds with less 
specificity for efflux transporters. The results indicated a 1.3- to 20-fold enhancement in 
the permeability of all the compounds evaluated. It is also demonstrated Pluronic® P85 
could enhance drug tissue drug permeability and facilitate antiretroviral efficacy in a 
severe combined immunodeficientcy (SCID) mouse model of viral encephalitis [24-26].   
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1.4.3. Liposomes 
Liposomes are artificially constructed vesicles that consist of an aqueous core 
separated from the continuous aqueous solvent by one or more spherical, bilayer 
membranes of surfactant molecules. Liposomes are composed of phospholipids, and 
may contain small amounts of other molecules that serve as cellular recognition markers 
and cholesterol that regulates membrane fluidity and stability. As drug delivery systems, 
liposomes have the capability of encapsulating both hydrophobic as well as hydrophilic 
payloads. Liposomes have several other benefits, such as solubilization improvement, 
protection of cargoes from enzymatic degradation and enhancement of intracellular 
uptake. Liposomes have been used to deliver antiretroviral agents to cross tissue 
barriers through receptor-mediated transcytosis. Besides, cell-penetrating peptides 
(CPP) and antibody conjugation are alternative approaches for liposomes to penetrate 
HIV reservoir. Mononuclear phagocytic system is another liposomal delivery mechanism, 
which can significantly increase the drug half-life in the central nervous system (CNS). 
Surface-engineered liposomes have been developed to target the lymphoid virus 
reservoir by incorporating surface charge or site-specific targeting ligands. Liposomes 
with negative surface charge have shown higher accumulation in lymph nodes and 
spleen compared to particles with positive charge [27].  
1.4.4. Nanosuspensions 
Nanoformulated antiretroviral therapeutics (nanoART) was developed in our 
laboratory in the past decade.  NanoART are polymer excipient coated drug 
nanosuspensions, which demonstrate high drug loading capacity, controllable size and 
charge, and tunable surface conjugation. Antiretroviral drugs could be formulated 
through high-pressure homogenization and wet milling for long-acting antiretroviral 
therapy. Mononuclear phagocyte targeted nanoART for delivery to HIV reservoirs was 
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developed with high drug loading, improved cell uptake and sustained drug retention. 
Drugs can be delivered into the target sites at levels above the effective therapeutic 
concentrations through mononuclear phagocytes. To improve pharmacokinetics and 
pharmacodynamics (PK/PD) of antiretroviral therapy, we further developed nanoART 
targeted to HIV reservoirs. Previous studies have shown that folate receptor (FOLR) is 
overexpressed on activated macrophages. Based on these findings, folate-decorated 
drug delivery systems have been developed to target macrophages for the treatment of 
inflammatory diseases with improved therapeutic efficacy. Folic acid was conjugated 
onto the coating excipient poloxamer 407 (P407) to generate folate-decorated nanoART 
for macrophage targeting. In vitro studies using a human MDM system, FA-nanoART 
showed a 2-fold increase in drug uptake, longer drug retention, and superior 
antiretroviral efficacy over non-targeted nanoART. In vivo PK/PD studies showed that 
FA-nanoART increased the plasma levels of ATV approximately 5-fold over that 
observed with non-targeted nanoART [28, 29]. 
1.4.5. Solid lipid nanoparticles  
Solid lipid nanoparticles (SLNs) usually comprise biocompatible lipids, that are 
solid at room temperature or surfactants for emulsification. They are typically solid 
particles consisting of one or more biocompatible solid lipids, which are stabilized by 
emulsifiers. The particle size ranges from approximately 50 to 1000 nm. They possess 
advantages like long retention, superior biocompatibility and biodegradability, excellent 
stability and loading capability as well as ease of introduction of targeting ligands. SLNs 
for CNS delivery of ART were developed, and the permeability of stavudine, delavirdine, 
and saquinavir encapsulated in different nanocarriers, including polymer nanoparticles 
and SLN, were tested across an artificial BBB. There was increased permeability of SLN 
encapsulated drugs compared to free drugs. In addition, delavirdine and saquinavir 
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loaded SLN showed better permeability than those loaded into polymer nanoparticles 
[30].  
1.4.6. Dendrimers 
Dendrimers are a highly branched complex multiple repeating structures of a 
monomer. They are comprised of hydrophobic cores and highly branched surface 
functional groups that make them ideal for transport of drugs across biological barriers. 
The end groups of these molecules can be functionalized to generate dendrimers that 
can be used as drug carriers and targeting moieties can be attached that influence 
biodistribution and toxicity of the dendrimers. Poly(amido amide) (PAMAM), the most 
commonly used dendrimer has been shown to incorporate several anticancer drugs. 
However, no dendrimer-based delivery systems have been approved for anti-HIV 
treatment due to their high cellular toxicity [31]. 
1.4.7 Nanomedicine in antiretroviral therapy 
Significant progress has been made to treat HIV/AIDS to improve the life quality of 
HIV infected people in the last decades. The utilization of nanomedicine in ART has 
successfully shifted rapidly progressive HIV infection to a disease with little detectable 
viral load in patients. It is still a big challenge so far to eradicate HIV due to the 
occurrence of drug resistance and viral reservoirs. Nanotechnology-based drug delivery 
systems can improve antiretroviral therapy by more precisely controlling drug 
concentrations in target cells and tissues, thus enhance uptake of antiretroviral agents 
into HIV-infected cell and tissue reservoirs and improve the pharmacokinetics, 
pharmacodynamics and biodistribution of antiretroviral agents using targeting ligands 
and improving drug delivery across tissue barriers. The goal of HIV eradication can be 
achieved through developing different nanomedicine platforms and decorating 
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nanomedicines with specific ligands to interact with receptors expressed on HIV infected 
cells. 
Nanomedicine has provided new tools and rationales in the development for novel 
strategies for HIV/AIDS treatment. The rational design has provided new candidates 
against HIV with improved solubility, stability and pharmacokinetic and adherence 
properties. Most current nanomedicine platforms focus on drug delivery in the blood and 
on improving pharmacokinetic profiles. Nanosustained drug release formulations could 
maintain plasma drug concentrations for weeks and even months. Although there are 
benefits and advantages of applying the systems approach to novel nanoformulations, 
there are still challenges that need to be overcome in the future to translate academic 
research into the clinical setting. These include the biocompatibility of excipients, safety, 
stability and the scale-up procedure for large-scale preparations. Nanomedicine 
platforms should be explored to develop combination therapies for safe and effective 
long-acting HIV therapy to improve patient compliance and life quality. 
1.5. Hypothesis and goals 
This study focuses on developing long-acting antiretroviral prodrug with enhanced 
hydrophobicity and stability. A hydrophobic lamivudine (3TC) prodrug is successfully 
synthesized and incorporated into targeted and non-targeted nanocrystalline 
formulations to improve drug half-life, enhance macrophage uptake, and sustain 
antiretroviral efficacy. Folic acid targeted parenteral nanoformulations are prepared for 
improved pharmacokinetics and improved antiretroviral therapy. This long-acting 
antiretroviral drug delivery system can serve both as drug transporters and as facilitators 
of viral clearance. Macrophage loading capacities and intracellular compartments of 
nanoparticle depots are studied. Macrophage endosomal compartments can be 
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harnessed for particle storage, release and drug trafficking. NanoART is expected to 
provide increased drug uptake, retention in macrophages, which facilitates its long acting 
antiretroviral efficacy. Macrophage can act as drug transporters for improved clinical 
stability and bioavailability. Regulation of phagolysosomal endocytic pathway is also 
studied. The co-localization of nanoformulated atazanavir  (ATV) at endosomal sites of 
viral assembly is expected to affect regulatory proteins and pathways that contribute to 
viral clearance. The cell targeted small magnetite ART (SMART) particles is developed 
to facilitate drug adherence and improve disease outcomes. Rapid noninvasive 
determination of drug biodistribution in virus-target tissues and reservoirs for nanoART 
can realize noninvasive assessments of antiretroviral drug tissue distribution through 









Chapter II.  
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Long-acting lamvudine prodrug 
design and formulation 
development   
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2.1. Abstract 
The next generation of antiretroviral medicines will be characterized by infrequent 
parenteral administration, maintenance of continuous drug concentrations and viral 
reservoir-targeted drugs. This will enable reductions in toxicities, viral loads and 
resistance patterns while improving drug regimen adherence. Perhaps most 
importantly such advances would facilitate viral clearance in infectious reservoirs that 
include gut-associated lymphoid tissue, lymphoid nodes, the genitourinary system and 
the central nervous system.  While such progress has been now realized for 
hydrophobic integrase and select nonnucleoside reverse transcriptase inhibitors, very 
limited success has been achieved with the more hydrophilic short-acting nucleosides. 
To overcome such limitations, we developed a two-step synthesis to create a long-
acting lamivudine (2’,3’-dideoxy-3’-thiacytidine, 3TC).  A stable hydrophobic pro-drug 
crystal formulation was produced by poloxamer drug encasement. Conversion of the 
formerly hydrophilic 3TC significantly extended its bioavailability facilitated by chemical 
drug conjugation to a fatty acid and creating a myristoylated drug. A folate targeted 
poloxamer 407 coated a newly formed nanocrystalline pro-drug markedly improving 
cell uptake, bioavailability and pharmacokinetic profiles. Reduced cytotoxicity and 
robust antiretroviral activities were also observed. These findings bring the idea of 
long-acting antiretroviral medicines closer to the mainstay of clinical availability.   
2.2. Introduction 
The introduction of nanomedicine in antiretroviral therapeutic regimens has 
impacted the treatment of HIV infection. Long-acting nanoformulated antiretroviral 
therapy (nanoART) has the real potential to improve patient adherence, decrease 
systemic toxicities, and sustain viral suppression [32-37]. However, the remaining 
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challenge to bring nanoART to the forefront of antiretroviral therapy is to 
nanoformulate a broad range of hydrophilic drugs. While hydrophilic drugs are widely 
used in the clinic, their drawbacks include the need for frequent administration by rapid 
clearance, low intracellular absorption and suboptimal biodistribution.  Cellular and 
tissue toxicities also reduce their clinical effectiveness. Ideal drug delivery systems and 
encapsulation strategies specifically for hydrophilic antiretroviral nucleoside reverse 
transcriptase inhibitors (NRTIs) are still under investigation. 
NRTIs are the backbone of combination antiretroviral therapy in the treatment of 
HIV infection [38-40]. Lamivudine (3TC) by competing with an endogenous nucleotide 
transcriptase enzyme leads to viral DNA chain termination that follows incorporation of 
the active 3TC phosphorylated anabolite in place of endogenous cytidine triphosphate 
during reverse transcription. 3TC has potent antiviral effects on HIV-1, HIV-2, and 
hepatitis B virus [41-44]. However, the drug is < 36% protein bound and with a half-life 
of 5-7 hours and rapid renal elimination by tubular secretion is catalogued as a short-
acting drug. These characteristics minimize its utility as a once daily fixed dose 
medicine. 
Myristoyltransferase (NMT) effects myristoylation of proteins during the HIV life 
cycle [45-47]. Fatty acid analogues of myristic acid can inhibit NMT and can be used to 
convert a hydrophilic 3TC into a hydrophobic drug [48-50]. Myristolic 3TC (MTC) was 
encased into a nanoparticle with poloxamer 407 with well-distributed size and stable 
physical properties. Folic acid, the ligand for the folate receptor expressed on 
macrophages, attached to drug nanoparticles can facilitate drug uptake [51, 52]. 
Moreover, for nanoART macrophage uptake, the targeting ligand folic acid can 
facilitate drug uptake and retention in monocyte-macrophages [53]. We developed 
targeted MTC nanoformulations using folate as a targeting ligand, enabling it to affect 
cellular uptake, antiretroviral efficacy, and antiretroviral pharmacokinetic behavior. The 
 26 
idea of formulating 3TC prodrug to improve therapeutic outcomes for patients receiving 
long-term antiretroviral treatment is novel and of significant potential utility. 
2.3. Materials and methods  
2.3.1. Reagents and antibodies.  
3TC was acquired from GlaxoSmithKline Inc. (Research Triangle Park, NC, USA). 
Poloxamer 407 (P407) and CF488-succinimidyl ester (CF488) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Sephadex LH-20 was obtained from GE 
Healthcare (Piscataway, NJ, USA). Pooled human serum was obtained from 
Innovative Biologics (Herndon, VA, USA). Macrophage colony-stimulating factor (M-
CSF) was prepared from 5/9m alpha3-18 cells (ATCC; CRL-10154) cultured in ATCC 
complete growth medium as described previously [54]. Rabbit anti-human antibodies 
to Rab5, Rab7, Rab11, and Rab14 and Alexa Fluor 568 goat anti-rabbit IgG were 
purchased from Santa Cruz Biotechnology (Dallas, TX, USA). TRIzol reagent was 
obtained from Invitrogen (Grand Island, NY, USA). 
2.3.2. Synthesis of hydrophobic 3TC derivative.  
The hydrophobic 3TC derivative (MTC) was synthesized according to the scheme 
shown in Figure 2.1A. Briefly, 3TC (4 mmol) was dissolved in dimethylformamide 
(DMF, 6 mL) in an ice bath, imidazole (6 mmol) and tert-butyldimethylsilyl chloride (4.8 
mmol) were added separately and the reaction mixture was stirred at room 
temperature (25 °C) overnight. After the completion of reaction, the reaction mixture 
was concentrated at reduced pressure and purified with silica gel column 
chromatography using dichloromethane and methanol (2-10%) as eluents. The yield 
compound was dissolved in dry pyridine (6 mL). A solution of 4,4’-dimethoxytrityl 
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chloride (DMTr-Cl, 8 mmol) was added to the reaction mixture dropwise at 0 °C. The 
temperature was raised to room temperature, and stirring was continued overnight. 
The reaction mixture was neutralized with saturated sodium bicarbonate solution (200 
mL) and extracted with dichloromethane (200 mL) for three times. The organic layer 
was separated and concentrated in vacuo. The residue was purified with silica gel 
column chromatography using dichloromethane and methanol (2-10%) as eluents. The 
yield compound was dissolved in tetrahydrofuran (THF, 6 mL) and 
tetrabutylammonium fluoride (6.2 mL, 1.5 molar ratio) was added dropwise and stirred 
for 4 h. The reaction mixture was concentrated at reduced pressure, and the residue 
was purified with silica gel column chromatography using dichloromethane and 
methanol (2-10%) as eluents. The yield compound was dissolved in DMF (10 mL). 
Then myristic acid acid (945 mg, 2 molar ratio), 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU, 1.72 g, 2.2 molar 
ratio) and N,N-diisopropylethylamine (DIEA, 1.5 mL, 3.4 molar ratio) were added to the 
mixture separately. The reaction mixture was concentrated at reduced pressure, and 
the residue was purified with silica gel column chromatography using dichloromethane 
with 2% methanol as eluents. Acetic acid (10 mL) was added to the yield compound 
and the reaction mixture was heated at 80 °C for 30 min. The reaction mixture was 
concentrated at reduced pressure, and the residue was purified with silica gel column 
chromatography using dichloromethane with 2% methanol as eluents. The chemical 
structure of final product was characterized by nuclear magnetic resonance 
spectrometry (1H NMR) determined on a Varian Unity/Inova-500 NB (500 MHz; Varian 
Medical Systems Inc., Palo Alto, CA, USA). Chemical shifts are reported in parts per 
million (ppm). The structure of the final compound was analyzed by FTIR spectroscopy 
using a Spectrum Two FT-IR spectrometer,(PerkinElmer, Waltham, MA, USA) .  
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2.3.3. NanoMTC manufacture and characterization.  
MTC nanoparticles were formulated by high-pressure homogenization (Avestin 
EmulsiFlex-C3; Avestin Inc., Ottawa, ON, Canada), using P407 and FA-P407 to 
encase the drug crystals. For the non-targeted MTC formulation (called NMTC), the 
suspension contained modified 3TC (1% [wt/vol]) and P407 (0.5% [wt/vol]) and for the 
targeted MTC formulation (called FA-NMTC), the suspension contained modified 3TC 
(1% [wt/vol]), P407 (0.3% [wt/vol]) and FA-P407 (0.2% [wt/vol]). The suspension was 
premixed overnight in 10mM HEPES buffer at room temperature and then 
homogenized at 20,000 PSI for about 360 passes until the desired particle size of 
about 350 nm was achieved. The size, zeta potential, and polydispersity (PDI) were 
determined by dynamic light scattering (DLS), using a Malvern Zetasizer Nano Series 
Nano-ZS (Malvern Instruments, Westborough, MA, USA). A minimum of 3 iterations 
were taken, which varied by < 2%. After reaching the desired size (around 300 nm), 
the sample was purified by centrifugation at 100 × g for 5 min to remove aggregated 
particles and then at 20,000 × g for 30 min to collect a purified particle pellet. The 
resulting particles were resuspended in 10 mM HEPES for further studies [55, 56]. 
2.3.4. Preparation of dye-labeled nanoMTC.  
For preparation of CF488-labeled nanoMTC, CF488-P407 and P407 were 
dissolved in methanol at a weight ratio of 1:4. The solvent was evaporated, and the 
mixture was resuspended with 10 mM HEPES to yield a 0.5% surfactant solution. 
Modified 3TC was added at a 1% weight ratio. The suspension was premixed 
overnight in a light-protected environment at room temperature. The suspension was 
homogenized by high-pressure homogenization and purified by centrifugation as 
described above. 
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2.3.5. Human monocyte isolation and cultivation.  
Human monocytes were obtained by leukapheresis from HIV-1-, HIV-2-, and 
hepatitis B-seronegative donors and then purified by countercurrent centrifugal 
elutriation. Cells were obtained following informed consent using a protocol approved 
by the University of Nebraska Medical Center Institutional Review Board. The 
recovered monocytes, >98% pure by Wright-stained cytosmears, were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat-inactivated pooled 
human serum, 1% glutamine, 50 µg/mL gentamicin, 10 µg/mL ciprofloxacin, and 1,000 
U/mL recombinant human macrophage colony stimulating factor for 7 days, facilitating 
cell differentiation into macrophages (MDM) [57]. 
2.3.6. Nanoformulated MTC particle stability.   
Formulated NMTC and FA-NMTC particles were dispersed in phosphate buffered 
saline (PBS) and placed into a 10 kDa dialysis tube in 2 L of PBS under stirring at 
37°C. At 30 min and 1, 2, 3, 4, 6, 8 and 10 days, 100 µL of the suspension was 
collected. The supernatant was dissolved in 900 µL methanol [58]. The amount of 
MTC was measured by high-performance liquid chromatography (HPLC). HPLC 
analysis was as previously described [59]. Triplicate 20-µL samples were assessed by 
HPLC using a Synergi 4 µm Hydro-RP 80A C18 column (Phenomenex Inc., Torrance, 
CA). The mobile phase, consisting of 80% acetonitrile-20% 5 mM Na2HPO4, pH 9.0, 
was pumped at 1.0 mL/min with UV-visible (Vis) detection at 272 nm. MTC 
concentration was determined by peak area comparison to those of a standard curve 
generated with free MTC (0.049 to 50 µg/mL) [60]. 
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2.3.7. Cytotoxicity studies.  
Cytotoxicity of native drug, modified drugs and the different nanoformulations was 
evaluated by Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies Inc, 
Rockville, MD, USA) [61]. Briefly, human monocytes were cultivated in a 96-well-plate 
at the density of 100,000 cells per well. After 7 days of differentiation, MDM were 
treated with native 3TC, MTC, NMTC, or FA-NMTC at a series of concentrations: 0.10, 
0.33, 1.0, 3.3, 10.0, 33.3, and 100 mM. Four hours after treatment, 10 µL of CCK-8 
was added to each well. The plate was incubated in a 5% CO2 incubator for 2 h after 
which the absorbance was measured at 450 nm using a microplate reader. The cell 
survival rate was calculated based on the equation below: 
 





𝐴𝑠𝑎𝑚𝑝𝑙𝑒: 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒,𝐴𝑏: 𝑏𝑙𝑎𝑛𝑘,𝐴𝑐: 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
2.3.8. Nanoformulated MTC particle cell uptake.  
Human monocytes were cultivated in a 12-well-plate at the density of 1.5 million 
cells per well. After 7 days of differentiation, MDM were treated with 100 µM 
nanoformulated MTC. Uptake of nanoMTC was assessed without medium changes for 
8 h. Adherent MDMs were collected by scraping into PBS, at 1, 2, 4 and 8 h after 
treatment. Cells were pelleted by centrifugation at 1000 × g for 8 min at 4°C. Cell 
pellets were briefly sonicated in 200 µL of methanol and centrifuged at 20,000 × g for 
10 min at 4°C. The MTC content in the cells was determined by HPLC. 
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2.3.9. Antiretroviral activities.  
Antiretroviral efficacy was determined by HIV-1 reverse transcriptase (RT) activity 
[62, 63]. Briefly, MDM were treated with 100 µM native 3TC, MTC or nanoformulated 
MTC for 4 h. Following treatment, cells were washed with PBS for three times and 
cultivated with fresh medium. At 0, 5, 10 and 15 days after treatment, cells were 
challenged with HIV-1ADA at a multiplicity of infection (MOI) of 0.1 infectious particles 
per cell. Following viral infection, the cells were cultured for another 7 days with half-
medium exchanges every other day. Medium samples were collected on days 7 for 
measurement of progeny virion production, as determined by RT activity. For 
assessment of RT activity, 10 µL medium samples were mixed with 10 µL of a solution 
containing 100 mM Tris-HCl (pH 7.9), 300 mM KCl, 100 mM dithiothreitol, 0.1% NP-40, 
and water in a 96-well plate. The reaction mixture was incubated at 37°C for 15 min, 
and 25 µL of a solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 5 mM 
dithiothreitol, 15 mM MgCl2, 0.05% NP-40, 10 µL/mL poly(A), 0.25 U/mL oligo, and 10 
µCi/mL [3H]dTTP was added to each well; the plates were incubated at 37°C for 18 h. 
Following incubation, 50 µL of cold 10% trichloroacetic acid was added to each well, 
the wells were harvested onto glass fiber filters, and the filters were assessed for 
[3H]dTTP incorporation by beta-scintillation spectroscopy using a TopCount NXT 
(PerkinElmer Inc., Waltham, MA, USA). 
2.3.10. Immunocytochemistry and confocal microscopy.  
For immunofluorescence staining, cells were washed three times with PBS and 
fixed with 4% paraformaldehyde (PFA) at room temperature for 30 min. The cells were 
treated with blocking/permeabilizing solution (0.1% Triton, 5% BSA in PBS) and 
quenched with 50 mM NH4Cl for 15 min. The cells were washed once with 0.1% Triton 
in PBS and sequentially incubated with primary and secondary antibodies at room 
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temperature. Slides were covered in ProLong Gold AntiFade reagent with DAPI (4’,6-
diamidino-2-phenylindole) and imaged using a 63× oil lens on an LSM 510 confocal 
microscope (Carl Zeiss Microimaging, Inc., Dublin, CA, USA) [28]. The 
immunofluorescence was quantitated, and the percent overlap was determined using 
ImageJ software, the JACoP plug-in for percent overlap, and Zeiss LSM 510 Image 
browser AIM software version 4.2 for determining the number of pixels and the mean 
intensity of each channel, as previously described [55]. The results are represented as 
means ± standard errors of the mean. 
2.3.11. HIV-1 p24 staining.  
Cells in different treatment groups were fixed with 4% phosphate-buffered PFA for 
15 min at room temperature. The fixed cells were blocked with 10% BSA in PBS 
containing1%Triton X-100 for 30 min at room temperature and incubated with mouse 
monoclonal antibodies to HIV-1 p24 (1:100; Dako, Carpinteria, CA, USA) for 3 h at 
room temperature. Binding of HIV-1 p24 antibody was detected using a Dako 
EnVision+ System, HRP-labeled polymer anti-mouse secondary antibody, and 
diaminobenzidine staining. Cell nuclei were counterstained with hematoxylin for 60 s. 
Images were taken using a Nikon TE300 microscope with a 40× objective [55, 64]. 
2.3.12. Pharmacokinetic studies.  
All animal studies were conducted humanely according to a protocol for animal 
experiments approved by the University of Nebraska Medical Center Institutional 
Animal Care and Use Committee. Male Balb/cJ mice (Jackson Labs, Bar Harbor, ME, 
USA) were maintained on a folate-deficient diet (Harlan Teklad TD.00434; Harlan 
Laboratories, Inc., Indianapolis, IN, USA) beginning 2 weeks prior to drug 
administration. Mice were injected with native 3TC, MTC, NMTC, FA-NMTC (50 mg/kg 
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based upon 3TC) or PBS intramuscularly (IM). Plasma was collected at 8 h, 1, 3, 5, 7, 
10 and 14 days after drug administration. Tissues (liver, kidney, brain, spleen, gut, 
lymph node and muscle) were collected after sacrifice on day 14. 3TC and MTC from 
plasma and tissues were extracted using acetonitrile and assayed by UPLC-MS/MS. In 
preparation for drug analysis, 3TC and MTC were extracted from plasma (20 µL) using 
1 mL of acetonitrile. Internal standard was added to each sample (10 µL) and 
consisted of 1.33 µg/mL deuterated-3 isotope of lamivudine (3TC), 0.665 µg/mL 
deuterated-4 isotope of ABC, and 0.5 µg/mL lopinavir. Samples were dried using a 
ThermoScientific Savant Speed Vacuum (ThermoScientific, Waltham, MA, USA), and 
reconstituted in 80% v/v methanol in Optima grade water. Standards were prepared 
with initial 3TC concentrations (ng/ml) of: 13,300; 5,320; 2,660; 1,330; 532; 266, 133; 
53.2; 26.6, 13.3; 5.32; 2.66; and 1.33 for final 3TC concentrations (ng/mL) of: 500, 
200, 100, 50, 20, 10, 5, 2, 1, 0.5, 0.2, 0.1 and 0.05. MTC standards had initial 
concentrations of (ng/mL): 5000, 2000, 1000, 500, 200, 100, 50, 20, 10, 5, 2, 1, and 
0.5 and the same final concentrations as the 3TC standards. Plasma standards were 
prepared by extracting 20 µL of blank plasma from control Balb/cJ mice 
(BioreclamationIVT, Hicksville, NY, USA) into 1 mL of acetonitrile. The same internal 
standard was added to each standard.  
For tissue preparation, 50-100 mg of liver, spleen and lymph node were 
homogenized in 4 volumes of an esterase inhibitor mixture (12.5 mg/mL sodium 
fluoride and 3.75 mg/mL EDTA solution in Optima grade water) and 2.5 µL of a 
protease inhibitor (10 mM PMSF in HPLC grade isopropanol). Tissue homogenate 
(100 µL) was mixed with 10 µL of internal standard (5 µg/mL deuterated-3 isotope of 
lamivudine (3TC), 2.5 µg/mL deuterated-4 isotope of ABC, and 2 µg/mL lopinavir) and 
extracted in 300 µL methanol. Supernatant was used directly for MTC analysis or 
mixed with water for 3TC analysis. Standards were prepared with initial 3TC 
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concentrations (ng/mL) of: 50,000; 20,000; 10,000; 5,000; 2,000; 1,000; 500; 200; 100; 
50; 20; 10; and 5 for final 3TC concentrations (ng/mL) of: 500, 200, 100, 50, 20, 10, 5, 
2, 1, 0.5, 0.2, 0.1 and 0.05. MTC standards had initial concentrations of (ng/mL): 
20,000, 8,000, 4,000, 2,000, 800, 400, 200, 80, 40, 20, 8, 4, and 2 and the same final 
concentrations as the 3TC standards. Tissue standards were prepared by 
homogenizing 50-100 mg of blank liver, spleen or lymph node from control Balb/cJ 
mice in 4 volumes of the same esterase and protease inhibitor mixtures as the 
samples. The same internal standard was added to each standard then extracted in 
300 µL of methanol. Drug quantitation was completed using a Waters ACQUITY H-
class UPLC system (Waters, Milford, MA, USA) connected to a Waters Xevo TQS-
micro mass spectrometer with an electrospray ionization (ESI) source. 
Chromatographic separation of 10 µL 3TC sample injections was achieved using 
an ACQUITY UPLC CSH C18 column (1.7 µm, 2.1 mm x 100 mm) using a 13 min 
gradient of mobile phase A (7.5 mM ammonium bicarbonate in Optima grade water 
and adjusted to pH 7 using glacial acetic acid) and mobile phase B (100% Optima 
grade methanol) at a flow rate of 0.25 mL/min. Initial mobile phase conditions of 90% A 
were held for 2.5 min, decreased to 5% A over 6.5 min, held at 5% A for 1.3 min, then 
increased to 90% A over 0.45 min and held for 2.25 min. MTC chromatographic 
separation was achieved using the same CSH column and mobile phases, but with a 
16 min isocratic method using 19% mobile phase A and flow rate of 0.3 mL/min. Drug 
was detected in the ESI positive mode with a cone voltage of 4 V and a collision 
energy of 10 V. Multiple reaction monitoring (MRM) transitions used for 3TC and MTC 
were 230.23 > 111.97 and 440.10 > 111.97 respectively. The deuterium-4 isotope of 
3TC was used as the internal standard for 3TC quantitation and had an MRM 
transition of 233.23 > 114.97. Lopinavir was used as the internal standard for MTC 
quantitation and had an MRM transition of 629.18 > 447.20. Spectra were analyzed 
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and quantified by MassLynx software version 4.1. All calculations were made using 
analyte peak area to internal standard peak area ratios. 
2.13. Statistics.  
All the data were analyzed by one-way analysis of variance (ANOVA) and Tukey’s 
multiple-comparison test using GraphPad Prism software (GraphPad Software, Inc., 
La Jolla, CA). All the cellular based experiments were replicated three times and the 
animal experiment was replicated twice. The sample size was determined according to 
published guidelines with a minimum of 5 animals per group (n=5). No outliers from 
animal or cell experiments were excluded. Differences were considered significant at a 
P value of <0.05. 
2.4. Results 
2.4.1. Characterization of chemically modified 3TC. 
A hydrophobic 3TC derivative (MTC) was synthesized successfully, as illustrated 
by the 1H NMR and FT-IR spectrum in Figure 2.1B and 1C. In the 1H NMR spectrum, 
chemical shifts of 0.9 and 1.3 ppm represented the 1° (RCH3) and 2° (R2CH2) aliphatic 
protons derived from the fatty acid chain. The protons connected to the ester (-H2C-
COOR) contributed to the peak at 2.4 ppm. In the FT-IR spectrum, the wavenumbers 
of 2917 and 2850 cm-1 were attributed to the C-H stretch, which belonged to the alkyl 
derivative derived from the fatty acid chain conjugated to the native 3TC; the 
wavenumber of 1692 cm-1 was attributed to the C=O stretch from the ester bond. The 
solubility of the hydrophobic MTC was determined to be 100 µg/mL in water, compared 
to 70 mg/mL water solubility of native 3TC. 
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2.4.2. Characterization of nanoformulated MTC.  
The nanoformulations were manufactured by high-pressure homogenization. 
Particle size, charge and PdI for all formulations were determined by dynamic light 
scattering (DLS). The schematic diagram of the targeted MTC particles was illustrated 
in Figure 2.1D and the characteristics of different formulations are summarized in 
Figure 2.2A. For FA-NMTC nanoparticles, a 40% FA-P407/60% P407 polymer solution 
was used to formulate the MTC. Both NMTC and FA-NMTC showed equivalent 
physicochemical characteristics. For NMTC nanoparticles, the particle size was 375 ± 
21 nm with a PdI of 0.21; while the FA-NMTC showed a slightly larger particle size of 
433 ± 23 nm with a PdI of 0.25. The zeta-potential for FA-NMTC decreased to -19.7 ± 
1.3 mV compared with -21.0 ± 0.8 mV for NMTC. The changes in size and zeta-
potential can be attributed to the FA conjugated to the P407 polymer. High drug 
loading (75.0% for NMTC, 76.9% for FA-NMTC) and encapsulation efficiency (96.3% 
for NMTC, 98.4% for FA-NMTC) were found for both formulations. 
2.4.3. Nanoformulated MTC particle stability.   
The stability of NMTC and FA-NMTC nanoformulations is illustrated in Figure 2.2B. 
There was no significant burst release in the first 8 h and sustained MTC 
concentrations were seen over 12 days. The cumulative MTC release reached 70.0% 
on day 3 and 94.8% on day 12 for NMTC, and 76.4% on day 3 and 96.7% on day 12 
for FA-NMTC.  
2.4.4. Cytotoxicity of nanoformulated MTC.  
Cytotoxicity of native 3TC, MTC and both nanoformulations was evaluated by Cell 
Counting Kit-8. MDM were treated with native 3TC, MTC, NMTC, or FA-NMTC at 
different concentrations for 4 h and cytotoxicity is shown in Figure 2.2C.  Native 3TC 
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showed strong cytotoxicity when the drug concentration increased to above 1 mM and 
the cell survival rate decreased to 9.6% at 3.3 mM. Compared with native 3TC, MTC 
shower much lower cytotoxicity. The cell survival rate was 95.9% at 3.3 mM and 
slightly decreased with the increment of drug concentration. The cytotoxicity for both 
nanoformulations was between native 3TC and MTC and no significant difference was 
observed between these two formulations.  
2.4.5. Macrophage uptake.  
MDM uptake of nanoformulated MTC was assessed and MTC levels were 
quantified by HPLC. Cells were exposed to nanoMTC for 8 h at 100 µM (42.7 g/mL) for 
both NMTC and FA-NMTC treatment. As shown in Figure 2.2D, the uptake of 
nanoMTC was increased over the first 2 h, and maximum uptake was observed at 2 h 
for both nanoformulations. At 2 h, the uptake of FA-NMTC was 24.88 µg/106 cells, 
which was more than 2 times higher than that of NMTC (10.45 µg/106 cells). After 2 h, 
cell drug levels began to decrease, and drug levels of MTC for NMTC and FA-NMTC 
at 8 h were 2.06 and 2.85 µg/106 cells, respectively. 
2.4.6. Antiretroviral activities of nanoformulated MTC.  
To assess the antiretroviral activity of nanoMTC treatment HIV-1 RT activity was 
determined in HIV-1-infected MDM treated with native 3TC, NMTC or FA-NMTC. Cells 
were treated with 100 µM of native 3TC or nanoformulated MTC for 4 hours. At this 
time the medium was removed, cells were washed 3 times with PBS and fresh 
medium without drug was added prior to HIV-1ADA challenge at days 0, 5 and 10 after 
treatment. Infected cells were cultured for an additional 7 days and RT activity in the 
culture medium was determined. Significant differences were found between cells 
treated with native 3TC or nanoformulated MTC. For native 3TC treated cells, RT 
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activity was suppressed only in the day 0 infection group. After day 5, the RT activity 
for the 3TC treated group increased dramatically over time, and no viral suppression 
was observed at day 15. In contrast, for nanoformulation treated groups, sustained 
antiretroviral activities were observed. The RT activities were suppressed to a 
relatively low level (< 25%) during the first 10 days. At day 15, the RT levels for NMTC 
and FA-NMTC were 59.8% and 68.5%, respectively, compared with 110.0% for the 
native 3TC group. Significant differences were observed between NMTC and FA-
NMTC during the first 10 days (p<0.05) and FA-NMTC showed greater antiretroviral 
activity compared with NMTC, however, the difference was not significant at day 15 
(Figure 2.3A). These results were confirmed by HIV-1 p24 staining (Figure 2.3B). 
NMTC and FA-NMTC showed greater antiretroviral efficacy compared with native 3TC, 
and much less p24 staining was observed in these two groups. FA-NMTC shower 
greater suppression of viral replication especially in the first 10 days, little to no p24 
antigen was detected in MDM treated with FA-NMTC. 
2.4.7. Immunocytochemistry and confocal microscopy.  
To assess subcellular behavior of the nanoformulated MTC particles, fluorescently-
labeled nanoparticles were used to visualize if co-localization of endolysosomal 
proteins and nanoMTC occured. CF488-labeled nanoMTC was prepared and Rab 5, 7, 
11, 14 and LAMP 1 were selected as targeted proteins. Immunostaining was 
performed 4 h after particle incubation for visualization of endocytic compartments and 
nanoMTC co-localization. As observed nanoMTC distributed in a punctate pattern 
throughout the cytoplasm and perinuclear cell regions (Figure 2.4). NanoMTC was 
found predominantly in late (Rab 7) and recycling (Rab 11 and 14) endosomes [51], 
and this immunofluorescence co-localization demonstrated that nanoMTC was taken 
and stored in macrophages through the endolysosomal pathways. Our previous 
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studies have demonstrated that the HIV reservoir exists mainly in late and recycling 
endosomes, and HIV-1 and nanoformulations deregulated cellular proteins in an 
opposing manner [56], supporting the idea of subcellular-targeted nanoparticles for 
long acting antiretroviral therapy. 
2.4.8. Pharmacokinetics.  
Balb/cJ mice were administered nanoformulated MTC at 50 mg/kg based on 3TC 
concentration to determine the pharmacokinetic parameters for both NMTC and FA-
NMTC as the scheme shown in Figure 2.5A. Plasma drug concentrations following 
formulation treatment were analyzed by UPLC-MS/MS and data are presented in 
Figure 2.5B and C. At each time point, very little MTC was detected, which indicated 
the complete conversion of MTC to 3TC. Higher and more sustained drug levels were 
observed for MTC nanoformulation treated groups and plasma drug levels were 
maintained over 10 days for both nanoformulations. At day 1, no drug could be 
detected in plasma from the native 3TC treated group; the drug levels for MTC, NMTC 
and FA-NMTC groups were 58.65 ± 6.94, 349.25 ± 12.51, and 383.24 ± 13.77 ng/mL, 
respectively. At day 3, little drug was detected in plasma from the MTC treated group, 
whereas plasma drug levels for NMTC and FA-NMTC groups were 131.30 ± 18.09 and 
151.63 ± 23.16 ng/mL, respectively. Compared with NMTC, FA targeted 
nanoformulation showed prolonged drug release and plasma drug levels were more 
than 2 fold higher than these of NMTC from day 5 to day 14.  At day 14, the plasma 
drug level for FA-NMTC was 22.66 ± 12.53 ng/mL and that for NMTC was at the limit 
of quantitation (< 0.5 ng/mL). Tissue drug levels are shown in Figure 2.5D; no 3TC 
was detected in tissues for mice treated with native 3TC or MTC after 14 days. Drug 
levels for the FA-NMTC treated group were greater than 2-fold higher than these for 
the NMTC group in liver, spleen and lymph nodes. 
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2.5. Discussion 
Reverse-transcriptase inhibitors are a class of antiretroviral drugs used to treat 
HIV/AIDS and hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA 
polymerase that is required for replication of HIV and other retroviruses.  Lamivudine 
(3TC) is a typical nucleoside analog reverse-transcriptase inhibitor (NRTI). Its 
favorable safety profile, low potential for drug interaction, good tolerability, and high 
resistance barrier makes it one of the preferred choices for HIV/AIDS therapy in 
multiple clinical scenarios. However, the low protein bound, short half-life and fast 
clearance of 3TC limit its clinical application. In this paper, we describe development of 
a nanoformulated 3TC prodrug in order to improve its clinical potential. 
Myristic acid was used to synthesize the hydrophobic MTC. This 14-carbon alkyl 
chain could significantly decrease the water solubility of native 3TC and improve the 
drug-protein, drug-membrane interactions during systemic circulation. In the presence 
of NMT, HIV-1 viral proteins are covalently attached to myristic acid, which exposes 
them to the antiretroviral drug sufficiently. It has been reported that NMT is a crucial 
enzyme involved in catalyzing the myristoylation of capsid protein p17, Pr160gag-pol, and 
Pr55gag, which are involved in the life cycle of HIV-1 [46]. Myristic acid has been shown 
to inhibit NMT [65-67]. HIV-1 replication could, consequently, be inhibited by the 
myristoylated 3TC. An ester bond was formed after chemical conjugation, which did 
not affect the antiretroviral efficacy of the prodrug, since the ester bond could be easily 
hydrolyzed in the presence of intracellular esterases, including lysosomal acid lipase, 
phospholipase, acetylhydrolase, nucleases and lipoprotein lipase, which are localized 
mainly in lysosomes. These enzymes catalyze the breakdown of acyl groups and 
hydrolyze compounds taken into lysosomes. In our study, the hydrophobic MTC 
presumably diffused through the cell membrane into different cell compartments. The 
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prodrug was transported into lysosomes, degraded by the esterases, and released the 
native 3TC to provide antiretroviral activity. Interestingly, MTC particles exhibited 
comparable antiretroviral efficacy to native 3TC as shown in day 0 RT result. Relatively 
low RT levels were observed in cells treated with both MTC formulations, which 
indicates that the myristoylation did not alter the antiretroviral efficacy of native 3TC. 
Myristoylated 3TC demonstrated reduced cytotoxicity compared with native 3TC, 
which could be attributed to the increased molecular weight; the enhanced 
hydrophobicity can also explain the reduced cytotoxicity since the solubility of MTC 
decreased dramatically. Compared to MTC, water-soluble 3TC, which is easily ionized 
in solution, can be cationized, influencing its complexation with the cell membrane, 
leading to higher cytotoxicity [68]. 
 
Nanocrystals are extraordinary drug delivery carriers and are useful because of 
their high drug loading capacity, improved stability and bioavailability [63, 69].  
Nanosize drug crystals can be coated with surfactant for enhanced cellular uptake and 
sustained cellular maintenance for long-acting efficacy. For drugs with a short half-life, 
like 3TC, the therapeutic index is limited due to the low bioavailability, therefore 
nanocrystals are ideal platforms for increasing drug retention and improving systemic 
circulation. P407 was used as a coating surfactant in order to provide stable 
nanosuspensions, improve nanoparticle dispersity, and realize long-term drug release. 
Both FA-targeted and non-targeted MTC nanoparticles were prepared with well-
distributed particle size and PdI. FA-NMTC exhibited a slightly larger size compared 
with NMTC due to the longer chain of FA-P407 coating polymer, but otherwise no 
significant difference was observed based on the characterization of the these two 
formulations. Both nanoformulations were stable in PBS and sustained drug release 
was observed in vitro, which demonstrated that this platform could be utilized to 
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manufacture particles with stable physiochemical properties and a sustained release 
profile. 
The FA-NMTC nanoparticles showed better cell uptake by macrophages, 
especially in the first 2 hours. These particles were expected to be taken through both 
phagocytosis and receptor-mediated endocytosis. Folate derivatives are internalized 
mainly through the reduced folate carrier (RFC), which binds to the reduced form of 
vitamin B9; and the folate receptor (FR), which has a high affinity for folic acid [70]. 
There are several different isoforms of FR including FR-α and FR-β, which are 
glycosylphosphatidylinositol-anchored proteins (GPI-AP) receptors. We have 
demonstrated in previous studies that FA coated nanoparticles are taken up by 
macrophages mainly through FR-β due to its overexpression in activated 
macrophages during myelopoiesis [53]. Especially for HIV-1 infected patients, FR-β 
will be highly expressed since the immune cells are activated [71, 72].  Meanwhile, 
nanoparticles can directly activate macrophages and more FR-β could be stimulated 
and overexpressed on the cell membrane of macrophages [53]. Both folate targeted 
and non-targeted MTC formulations can be taken up by macrophages through clathrin 
mediated endocytosis. Particles undergo recognition in the blood stream through 
opsonization and the opsonized particles attach to the cell membrane and are ingested 
into phagosomes [73]. The folate conjugated MTC nanoparticles are internalized by 
macrophages preferentially through a clathrin-independent pathway by the effect of 
FR-β. Folate attached to the MTC particles binds to GPI-anchored folate receptor, FR-
β, which is overexpressed on the macrophage surface [74]. This process facilitates the 
internalization of the MTC particles, which can explain the 2-fold difference after 2 h 
treatment and the enhanced antiretroviral activity compared with the non-targeted 
nanoformulation. Due to the enhanced cell uptake, FA-NMTC exhibited greater 
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antiretroviral activity than non-targeted NMTC as confirmed by RT assay and HIV-1 
p24 staining. Greater protection against HIV-1 was observed for targeted nanoparticles 
and the significant differences lasted for 10 days. Equivalent antiretroviral efficacy for 
both formulations by day 15 could be because most of the drug had been released by 
that time; however, both formulations showed greater antiretroviral efficacy compared 
with native 3TC. 
It has been proved that endolysosomes can be affected by HIV-1 infection through 
Rab protein expression, and endosomes are sites of active viral assembly, where a 
great amount of virions accumulate during productive infection [55, 56]. 
Endolysosomal pathways are vital to the transport antimicrobial drugs since they 
enable the drug particles to re-locate at specific sites where virus produces and 
duplicates. We investigated the intracellular localization of non-targeted MTC particles 
in macrophages. We found they predominantly co-localized in late (Rab 7) and 
recycling (Rab 11 and 14) endosomes and lysosomes (LAMP1), which it demonstrated 
that nanoMTC was taken up and stored in macrophages through the endolysosomal 
pathways. MTC particles contained within endocytic compartments would provide a 
protected environment to facilitate drug release with steady antiretroviral efficacy. This 
not only provides effective drug delivery to HIV-1 action sites for improved therapeutic 
efficacy, but also protects the particles from intracellular degradation. 
To investigate the in vivo pharmacokinetic parameters of nanoformulated MTC, we 
treated the mice with 50 mg/kg 3TC equivalents based as native 3TC, pro-drug MTC 
or nanoformulated MTC. Nanoformulated MTC exhibited sustained drug release and 
the folate coated MTC formulation exhibited 2-fold enhanced plasma and tissue drug 
levels compared with non-coated formulation in. Even after two weeks, the plasma 
level for FA-NMTC was still greater than three times higher than the half maximal 
effective concentration (EC50) of 3TC (about 6.9 ng/mL). These studies also 
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demonstrated that the targeted MTC particles were more effectively stored in the 
macrophage depots after injection, as evidenced by their localization in 
reticuloendothelia tissues and lymph nodes. NanoMTC were taken by monocytes in 
blood, and redistributed during systemic circulation to reticuloendothelial tissues. In 
macrophages, MTC was gradually released into the endosomal compartments and 
converted to native 3TC by hydrolases. In vivo MTC was efficiently converted to 3TC 
since little MTC was detected in plasma and tissues. Due to effective binding to the FR 
on macrophages, more FA-NMTC particles could be taken up by 
monocyte/macrophages, distributed into different cellular compartments, and avoid 
degradation by lysosomes, all of which would explain the higher in vitro uptake and 
more sustained in vivo pharmacokinetic behavior for FA targeted MTC particles. 
2.6. Conclusions 
A hydrophobic 3TC prodrug was successfully synthesized through myristoylation 
and incorporated into targeted and non-targeted nanocrystalline formulation to improve 
drug half-life and reduce cytotoxicity. Nanoformulated MTC exhibited enhanced 
cellular uptake and sustained antiretroviral efficacy. Folate targeted MTC nanoparticles 
exhibited improved pharmacokinetics and this novel drug delivery system has showed 




Figure 2.1. Characterization of myristoylated 3TC.  
(A) Synthesis of myristoylated 3TC (MTC) derivative. (B) The 1H NMR spectrum of MTC. 
MTC was dissolved in Dichloromethane-d2 and characterized by nuclear magnetic 
resonance spectrometry (1H NMR) determined on a Varian Unity/Inova-500 NB. 
Chemical shifts are reported in parts per millions (ppm). (C) FT-IR spectra of MTC and 
native 3TC. MTC and 3TC powder was analyzed by Spectrum Two FT-IR Spectroscopy 
to detect the structure of the final compounds. (D). Schematic diagram of the FA-NMTC 
formulation. Hydrophilic 3TC was myristoylated into hydrophobic MTC, and FA-




Figure 2.2. Characterization of MTC formulations  
(A) Characteristics of MTC nanoformulations. (B) Cumulative release of MTC in 
isotonic solution. (C) Cytotoxicity of nanoformulated MTC. Cytotoxicity of native 3TC, 
MTC and both formulations was evaluated by Cell Counting Kit-8. MDM were treated 
with native 3TC, MTC, NMTC, or FA-NMTC at different concentrations for 4 h and 
cytotoxicity was determined. The difference between 3TC and MTC at concentrations 
1.0, 3.3, 10.0, 33.3, and 100 mM are significant (P < 0.05). (D) Time course of uptake 
of MTC formulations in human MDM.. MDM were treated with 100 µM 
nanoformulations (based on MTC content) for 1, 2, 4 and 8 h. The cell lysates at 
indicated times were analyzed by HPLC for MTC quantification. Data represent the 





Figure 2.3. Antiretroviral efficacy of MTC nanoformulations.  
(A) HIV-1 RT activity of native 3TC and nanoformulated MTC. (B) HIV-1 p24 staining 
of virus-infected MDM pretreated with native 3TC or nanoformulated MTC. MDM were 
treated with 100 µM native 3TC or nanoMTC for 4 h. At days 0, 5, 10, or 15, MDM 
were infected with HIV-1 for 4 h. Uninfected cells without treatment served as a 
negative control; HIV-1 infected cells without treatment served as a positive control for 
the RT assay. All the samples were collected after 7 days of viral infections for RT 
assay and HIV-1 p24 staining. For RT activity, results are shown as the mean of 5 
replicates. The differences between 3TC and nanoMTCs (NMTC and FA-NMTC) at 
days 5, 10 and 15 are significant (P < 0.05). The differences between NMTC and FA-





Figure 2.4. Subcellular localization of nanoformulated MTC in MDM.  
MDM were cultured for 7 days and treated with 100 µM CF488-labeled NMTC for 4 h. 
The cells were stained with Rab 5, 7, 11, or 14 primary antibodies and AlexaFluor 568-
labeled secondary antibodies to visualize the corresponding cell compartments using 
confocal microscopy. Nanoparticles are shown in green, cell compartments in red, and 
nuclei in blue. 
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Figure 2.5. Plasma drug levels of nanoformulated MTC in Balb/C mice. 
 (A) Scheme of the pharmacokinetic study design. (B) Plasma drug levels from 8h to 
day 3. (C) Plasma drug levels from day 5 to 14. (D) Drug levels in liver, spleen and 
lymph node with formulations treated mice at day 14. Mice were administered 
intramuscularly (IM) 50 mg /kg equivalents of 3TC using native 3TC, MTC or MTC 
nanoformulations.  Plasma was collected into acetonitrile for drug analysis at 8 h, and 
days 1, 3, 5, 7, 10 and 14 after treatment and tissues were collected at day 14 after 
sacrifice. 3TC levels were determined by UPLC-MS/MS. Data are expressed as mean 
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3.1. Abstract 
Limitations in antiretroviral therapy (ART) include poor patient adherence, drug toxicities, 
viral resistance and failures to penetrate viral reservoirs. Recent developments of 
nanoformulated ART (nanoART) could overcome such limitations. To this end, we now 
report a novel effect of nanoART that facilitates drug depots within intracellular 
compartments at sites at or adjacent to the viral replication cycle. Poloxamer 407 coated 
nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-
pressure homogenization. These drug particles readily accumulated in human 
monocyte-derived macrophages (MDM). NanoATV concentrations were ~1,000 times 
higher in cells than what could be achieved by native drug. ATV particles in late and 
recycling endosome compartments were seen following pull down by immunoaffinity 
chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal 
microscopy provided cross validation by immunofluorescent staining of compartments. 
Mathematical modeling validated drug-endosomal interactions. Measures of reverse 
transcriptase activity and HIV-1p24 levels in culture media and cells showed that such 
endosomal drug concentrations enhanced antiviral responses up to 1,000 fold. We 
conclude that late and recycling endosomes can serve as depots for nanoATV. The co-
localization of nanoATV at endosomal sites of viral assembly and its slow release sped 
antiretroviral activities.  Long acting nanoART can serve as a drug carrier in both cells 
and subcellular compartments and as such facilitate viral clearance. The need for long 
acting ART is significant and highlighted by limitations in drug access, toxicity, 
adherence and reservoir penetrance.  We propose that targeting nanoformulated drugs 
to infected tissues, cells and subcellular sites of viral replication may improve clinical 
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outcomes.  Endosomes are sites for human immunodeficiency virus assembly and 
increasing ART concentration to such sites enhances viral clearance.  The current work 
uncovers a new mechanism for why nanoART can enhance viral clearance over native 
drug formulations.  
3.2. Introduction 
Long-acting nanoformulated antiretroviral therapy (nanoART) can result in improved 
patient adherence, decreased systemic toxicities and sustained viral suppression. This is 
seen through nanoART’s abilities to maintain consistent plasma and tissue drug levels 
[75-78]. Nonetheless, to facilitate clearance of the human immunodeficiency virus type 
one (HIV-1), antiretroviral drugs need be effectively delivered to viral sanctuaries [62]. 
This can target persistent or restricted infection [53, 79, 80]. With this in mind, our 
laboratories pioneered the use of monocytes and monocyte-derived macrophages (MDM) 
as nanoART carriers and drug depots. Macrophages can increase drug stability by 
preventing drug metabolic degradation and because of their highly mobile nature, they 
may also be used for delivery of ART to and from lymphocytes and other viral reservoirs 
[81-83]. How drug nanoparticles remain sequestered in macrophages for extended 
periods is incompletely understood. What is known is that nanoART can be delivered to 
endosomal organelles through clathrin-endosome pathways and remain inside the cell 
for extended time periods [81]. However, the virologic consequences of such a cell 
delivery system have not yet been elucidated. Investigations of nanoparticle interactions 
at the subcellular level remain of vital importance to the fields of long-acting antiretroviral 
pharmacokinetics and pharmacodynamics.  
     We reasoned that such mechanisms could be elucidated through investigations of 
nanoformulated viral protease inhibitors (PI). PI are substrate analogs for the HIV 
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aspartyl protease enzyme, involved in processing viral proteins by cleaving precursor 
proteins into smaller fragments and enabling the release of mature viral particles from 
infected cells. Once bound to the active site, they block the viral protease and in turn 
inhibit viral maturation, which blocks the formation of replication competent virions [84, 
85]. Atazanavir (ATV), a United States Food and Drug Administration-approved PI for 
the treatment of HIV-1 infection can selectively inhibit virus-specific processing of gag-
pol polyproteins. As a consequence PIs block viral assembly at action sites [86]. 
    It is well known that subcellular organelles are utilized for HIV-1 assembly in 
mononuclear phagocytes (MP; monocytes and tissue macrophages) [87, 88]. Indeed, 
large caches of infectious HIV-1 released from MDM are produced in late endosomes 
[89]. We thus reasoned that if nanoART can improve drug delivery to tissues and cells 
and affect viral clearance, its effects could be amplified if the PI is delivered to the late 
endosomal sites operative for viral assembly. Herein, we demonstrate that nanoART 
enhances its antiretroviral efficacy by being delivered to subcellular sites of active viral 
replication. By tracking endosomal nanoART transport, sequential immunoaffinity 
separations of cellular compartments and by developing computer assisted 
mathematical models we were able to track the antiretroviral drug activities inside 
macrophages. Antiretroviral responses as measured by reverse transcriptase (RT) 
activityand HIV-1p24 antigen provided evidence for the co-localization of nanoART and 
progeny virus. Mathematical modeling uncovered the pathways for nanoparticle 
trafficking through endosomal compartments [90]. Previous combinations of 
experimental and computational studies were limited by the inherent complexity of 
integrating simulated modals with experimental results [91]. The nanoparticle-subcellular 
compartment modeling supports the idea that nanoformulations can facilitate the use of 
macrophages as drug carriers for ART and thus facilitate the establishment of drug 
depots and speed of viral clearance. 
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3.3. Materials and methods 
3.3.1. Reagents & antibodies 
ATV sulfate purchased from Longshem Co (Shanghai, China) was free-based with 
triethylamine. Poloxamer 407 (P407) and CF568-succinimidyl ester (CF568) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA).  Sephadex LH-20 was obtained from 
GE HealthCare (Piscataway, NJ, USA). Pooled human serum was obtained from 
Innovative Biologics (Herndon, VA, USA). Macrophage colony stimulating factor (MCSF) 
was prepared from 5/9m alpha3-18 cells (ATCC®, CRL-10154TM) cultured in ATCC 
complete growth medium as described [20]. Rabbit anti-human antibodies to Rab5, 
Rab7, Rab11 and Rab14, and Alexa Fluor 488 goat anti-rabbit IgG were purchased from 
Santa Cruz Biotechnology (Dallas, TX, USA). Protein A/G mix magnetic beads were 
purchased from Millipore (Billerica, MA, USA). TRIzol reagent was obtained from 
Invitrogen (Grand Island, NY, USA). 
3.3.2. NanoATV manufacture and characterization 
ATV nanoparticles were formulated by high-pressure homogenization (Avestin 
EmulsiFlex-C3, Avestin Inc., Ottawa, ON, Canada) using P407 to encase the drug 
crystals. The suspension containing free-based ATV (1%, w/v) and P407 (0.5%, w/v) in 
10 mM HEPES buffer was premixed overnight at room temperature then homogenized 
at 20,000 psi for ~30 passes until the desired particle size of <300 nm was achieved. 
Size, zeta-potential and polydispersity (PDI) were determined by dynamic light scattering 
(DLS) using a Malvern Zetasizer Nano Series Nano-ZS (Malvern Instruments, 
Westborough, MA, USA). A minimum of four iterations were taken and these varied by < 
2%. After reaching the desired size (< 300 nm) the sample was purified by centrifugation 
at 500 × g for 5 min to remove aggregated particles, then at 10,000 × g for 30 min to 
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collect a purified particle pellet. The resulting particles were resuspended in a 0.2% (w/v) 
P407 surfactant solution for cell studies. 
3.3.3. Synthesis of dye-labeled nanoATV  
For preparation of CF568-labeled nanoATV, CF568-P407 and P407 were dissolved in 
methanol at a weight ratio of 1:4 [6]. The solvent was evaporated and the mixture 
resuspended with 10mM HEPES to yield a 0.5% surfactant solution. Free-based ATV 
was added at a 1% weight ratio. The suspension was premixed overnight in a light 
protected environment at room temperature. The suspension was homogenized by high-
pressure homogenization and purified by centrifugation [10].  
3.3.4. Human monocyte isolation and cultivation 
Human monocytes were obtained by leukapheresis from HIV-1,2 and hepatitis B 
seronegative donors then purified by counter-current centrifugal elutriation. The 
recovered monocytes, >98% pure by Wright stained cytosmears, were cultured in 
Dulbecco’s Modified Eagle’s Media (DMEM) with 10% heat-inactivated pooled human 
serum, 1% glutamine, 50 µg/mL gentamicin, 10 µg/mL ciprofloxacin and 1000 U/mL 
recombinant human MCSF for seven days facilitating cell differentiation into 
macrophages (MDM) [57].  
3.3.5. Native and nanoformulated ATV cell uptake and retention 
MDM were treated with native ATV or nanoATV at 30 or 70 µg/ml. Uptake of drug was 
assessed without media change for 24h. Cell collection occurred at serial time points. 
After 24 h drug exposure, drug retention in MDM was evaluated. Adherent MDM were 
collected by washing 3X with 1 mL of phosphate buffered saline (PBS), followed by 
scraping cells into 1 mL PBS. Samples were centrifuged at 950 × g for 10 min and 
supernatant removed. The cell pellets were resuspended in 200 µL methanol and 
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sonicated with a probe sonicator. The methanol extracts were centrifuged at 20,000 × g 
for 10 min prior to high performance liquid chromatography (HPLC) analysis as 
previously described [63].  Triplicate 20 µL samples of cells were assessed by HPLC 
using a YMC Pack Octyl C8 column (Waters Inc., Millford, MA) with a C8 guard 
cartridge. Mobile phase consisting of 47% acetonitrile/53% 25mM KH2PO4, pH 4.15, was 
pumped at 0.4 mL/min with UV/Vis detection at 212 nm. ATV levels in cells were 
determined by peak area comparisons to those of a standard curve generated with free 
drug (0.025-50 µg/mL). 
3.3.6. Immune isolation of endocytic subcellular compartments 
Immune isolation of endocytic compartments was performed as previously described 
[81]. Briefly, MDM were treated with native or nanoATV for 16 h. Cells were washed 3X 
in PBS to remove extracellular drug and then scraped in homogenization buffer (10 mM 
HEPS-KOH, pH 7.2, 250 mM sucrose, 1 mM EDTA, and 1 mM Mg(OAc)2). Cells were 
then disrupted by 15 strokes in a dounce homogenizer. Nuclei and unbroken cells were 
removed by centrifugation at 400 × g for 10 min at 40C. Twenty µL of slurry protein A/G 
paramagnetic beads conjugated to Rab 5, 7, 11 or 14 antibodies (binding in 10% BSA in 
PBS for 12 h at 40C) were incubated with cell supernatants. Following a 24 h incubation 
at 40C, Rab 5, 7, 11, and 14+ endocytic compartments were washed with PBS then 
collected on a magnetic separator. The drug content of each compartment was 
determined by HPLC [81]. 
3.3.7. Detection of HIV-1 integration by polymerase chain reaction (PCR) 
To estimate the HIV integration, a modified method of that developed by O’Diherty and 
colleagues was employed [92]. After seven days of culture, MDM were treated with 100 
µM native or nanoATV for 16 h then challenged with HIV-1ADA at a multiplicity of infection 
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(MOI) of 0.1 infectious viral particles/cell. Following viral infection for 4 h, cells were 
cultured for an additional 14 days with half media exchanges every other day before the 
cells were scraped for collection. TRIzol Reagent was used to isolate DNA and RNA 
samples. The number of proviruses/cell was determined by a kinetic PCR assay. The 
standard curve was derived by running the nested PCR protocol on several dilutions of 
the integrated standard nucleic acid samples [93]. The concentrations of human 
genomes in the isolated sample DNA (or RNA) were determined by OD260/280.  
3.3.8. Antiretroviral activities  
Antiretroviral efficacy was determined by HIV-1 RT activity [57, 94]. Briefly, MDM were 
treated with 100 µM native- or nano-ATV for 16 h and then challenged with HIV-1ADA at a 
MOI of 0.1. Following viral infection, cells were cultured for 14 days with half media 
exchanges every other day. Medium samples were collected on days 2, 4, 6, 8, 10, 12 
and 14 for measurement of progeny virion production as assayed by RT activity. Here, 
10 µL media samples were mixed with 10 µL of a solution containing 100 mM Tris-HCl 
(pH 7.9), 300 mM KCl, 100 mM dithiothreitol, 0.1% nonyl phenoxylpolyethoxylethanol-40 
(NP-40) and water in a 96-well plate. The reaction mixture was incubated at 370C for 15 
min and 25 µL of a solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 5 mM 
dithiothreitol, 15 mM MgCl2, 0.05% NP-40, 10 µL/mL poly(A), 0.25 U/mL oligo d(T), and 
10 µCi/mL 3H-thymidine triphosphate was added to each well; plates were incubated at 
370C for 18 h. Following incubation, 50 µL of cold 10% TCA was added to each well, the 
wells were harvested onto glass fiber filters, and the filters were assessed for 3H-
thymidine triphosphate incorporation by beta-scintillation spectroscopy using a TopCount 
NXT (PerkinElmer Inc., Waltham, MA, USA). 
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3.3.9. Immunocytochemistry and confocal microscopy 
For immunofluorescence staining, cells were washed three times with PBS and fixed 
with 4% paraformaldehyde (PFA) at room temperature for 30 min. Cells were treated 
with blocking/permeabilizing solution (0.1% Triton, 5% bovine serum albumin (BSA) in 
PBS) and quenched with 50 mM NH4Cl for 15 min. Cells were washed once with 0.1% 
Triton in PBS and sequentially incubated with primary and secondary antibody at room 
temperature. Slides were covered in ProLong Gold anti-fading reagent with DAPI and 
imaged using a 63× oil lens in a LSM 510 confocal microscope (Carl Zeiss 
Microimaging, Inc., Dublin, CA, USA) [28]. 
3.3.10. HIV-1p24 staining  
Cells in different treatment groups were fixed with 4% phosphate-buffered PFA for 15 
min at room temperature. Fixed cells were blocked with 10% BSA in PBS containing 1% 
Triton X-100 for 30 min at room temperature and incubated with mouse monoclonal 
antibodies to HIV-1p24 (1:100; Dako, Carpinteria, CA, USA) for 3 h at room temperature. 
Binding of HIV-1p24 antibody was detected using a Dako EnVision+ System-HRP 
labeled polymer anti-mouse secondary antibody and diaminobenzidine staining. Cell 
nuclei were counter stained with hematoxylin for 60 s. Images were taken using a Nikon 
TE300 microscope with a 40 × objective. Quantitation of immunostaining was performed 
by densitometry using ImagePro Plus, v. 4.0 [95].  
3.4. Results 
3.4.1. NanoART characterization 
 The nanoATV particles were formulated as a nanosized drug crystal from free-base 
ATV and P407. Physical properties including size, PDI and zeta potential were 
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measured by DLS. The particle size was 371.7 nm with a PDI of 0.194, which indicated 
the majority of nanoATV particles were homogeneous.  The zeta potential was -28.9 mV, 
and the negative charge was contributed by P407.  Scanning electron microscopy 
revealed smooth rod-like morphologies for the nanoATV particles and confirmed size 
measurements and distribution, which was consistent with our previous studies [81, 82]. 
3.4.2. Native and nanoATV cell uptake and retention 
MDM uptake and retention of drug were assessed by HPLC. Cells were exposed to 
native ATV or nanoATV for 24 h and two treatment concentrations (30 and 70 µg/mL) 
were used. Significant differences were observed in rate and extent of drug uptake 
between native and nanoATV treatment groups (Figure 3.1A). The uptake of nanoATV 
was found to increase with time and the maximum uptake was observed at 16 h for 70 
µg/mL treatment group (53.5 µg ATV/106 cells) and 24 h for 30 µg/mL (23.7 µg ATV/106 
cells). However, uptake of less than 0.1 µg ATV/106 cells was observed at 24 h for both 
native ATV treatment groups, and this was not time-dependent. Drug retention in MDM 
was determined 24 h after treatment.  In MDM treated with nanoATV, drug levels of 28.5 
µg/106 cells and 14.0 µg/106 cells in 70 and 30 µg/mL treatment groups, respectively, 
were sustained over 24 h. Sustained release was expected for up to 15 days with 
nanoparticle treatment based on previous studies [53, 82]. Much less ATV was detected 
24 h following treatment with native ATV. 
3.4.3. Antiretroviral activities of native and nanoATV 
To estimate the level of HIV-1 DNA and RNA PCR amplification assays were employed. 
After seven days of cultivation, MDM were treated with 100 µM native or nanoATV for 16 
h then challenged with HIV-1ADA at a MOI of 0.1. Following infection, cells were cultured 
for 14 days with half media exchanges every other day before cell collections. Isolated 
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total cell DNA or RNA were quantitated by kinetic PCR and nucleic acid levels calculated 
using standard curves made by the linear regression analyses. These data are shown in 
Figure 3.1C and D. At day 14 after HIV-1 challenge, 1.15 × 104 and 1.05 × 104 viral 
copies/103 MDM of viral DNA and RNA, respectively were determined in infected 
samples. Viral copies paralleled the concentrations of native ATV where 1 µM of ATV 
failed to show significant antiretroviral activity. In contrast for nanoATV treated groups, 
viral DNA and RNA was effectively suppressed at 1 µM. Viral copies were 29.59 and 
36.09/103 MDM for HIV-1 DNA and RNA, respectively. This was seen following 100 µM 
nanoATV treatment, which effectively suppressed viral replication.   
    To determine the levels of progeny virus produced in native and nanoATV treated 
cultures we treated MDM with native or nanoATV in increasing drug concentrations of 
0.01, 0.1, 1, 10, and 100 µM. Treatment was for 16 h with subsequent HIV-1ADA 
challenge at a MOI of 0.1. The same formulation used for cell uptake and retention was 
tested for antiretroviral activities to ensure that the results were comparable. Infected 
cells were cultured for 14 days with half media change every other day. Culture 
supernatants were collected at days 2, 4, 6, 8, 10, 12, and 14 for determination of 
progeny virion production assayed by RT activity. A dose-dependent effect on RT 
activity for native and nanoATV at all time points was observed (Figure 3.1E and F). 
Significant differences between native and nanoATV were seen. For native ATV treated 
cells, suppression of RT activity was maintained over time only at 100 µM, and most of 
the other native drug concentrations failed to show significant viral suppression 
compared to untreated controls.  In contrast, nanoATV reduced RT activity effectively 
starting at 1 µM. A two-log increase in viral suppression was seen with nanoATV as 
compared to native ATV.  
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3.4.4. NanoATV effects on HIV-1 p24 antigen 
Cross validation of the results shown above was made through evaluation of viral 
antigen expression following native and nanoATV treatments for infected cell cultures. 
The expression of HIV-1 p24 antigen was used to determine antiretroviral activity in 
MDM that were treated with native or nanoATV and subsequently challenged with HIV-1 
at a MOI of 0.1. Evaluation of p24 expression by infected MDM treated with native or 
nanoATV showed a concentration-response effect on the HIV-1 p24 expression at day 
14 following viral exposure (Figure 3.2). Higher treatment concentrations resulted in 
lower p24 expression for both treatment groups. Formation of multinucleated giant cells 
was also observed. Significant differences between the native and nanoATV were seen 
at all concentrations. The expression of HIV-1 p24 antigen decreased slightly in cells 
treated with 1 or 10 µM native ATV, but an 89.4% decrease was found in cells treated 
with 100 µM native ATV (data not shown). HIV-1 p24 expression in cells was reduced 
with all concentrations of nanoATV. Viral suppression was to nearly asymptomatic levels 
with nanoATV treatment; i.e. 90.9, 94.2 and 95.7% for 1, 10 and 100 µM nanoATV 
treatment, respectively (data not shown).  
3.4.5. NanoATV subcellular distributions 
Confocal microscopy enabled both visualization and quantitation of the subcellular 
nanoATV distribution in early (Rab 5), late (Rab 7) and recycling (Rab 11, 14) endocytic 
compartments [96]. In these experiments, MDM were treated with 100 µM nanoATV 
fluorescently labeled with CF568. Immunostaining was performed 16 h after particle 
incubation for visualization of endocytic compartments and nanoATV co-localization. 
These experiments showed nanoATV distribution in a punctate pattern throughout the 
cytoplasm and perinuclear cell regions.  NanoATV was found predominantly in late and 
recycling endosomes of uninfected macrophages (Figure 3.3A). Quantitation of the 
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fluorophore labeled Rab species in endosomes with CF568 (fluorescent)-labeled 
nanoATV was made by adapting Pearson’s correlation coefficient to measure only 
positive co-localization coefficients (i.e. M1 and M2) of the two fluorophores at different 
emission wavelengths. Based on this, we showed significant accumulation (p< 0.001) of 
nanoATV within Rab 5- (35.4 ± 5%), Rab 7- (65.1 ± 7%), Rab 11- (70.3 ± 11%) and Rab 
14- (56.9 ± 12%), positive compartments. To assess subcellular co-localization of 
nanoATV with assembled HIV-1 virions, MDM were treated with 100µM CF568-labeled 
nanoATV for 16 h following 14 days of HIV-1ADA infection. Identical Rab-specific 
antibodies were employed to immunostain endocytic compartments in multinucleated 
giant cells. Quantitation of fluorophore in Rab compartments showed clear co-
localization between virus and the nanoparticles (Figure 3.3B and 3D). The greatest 
amount of dual co-localization was found in Rab 7-immunopositive late endosomes. 
These data indicated that after HIV-1 infection, nanoATV persists in late endosomal 
compartments, the site of active viral assembly, but at half the level present in recycling 
endosomes of uninfected macrophages (3.3C vs. 3.3D). 
3.4.6. NanoATV trafficking in endosomal subcellular comparments 
To assess the locale of nanoATV at the subcellular level we analyzed individual 
endosomal compartments within MDM by immunoaffinity techniques. MDM exposed to 
nanoATV were mechanically disrupted at specific time points, and subcellular 
compartments including early, late and recycling endosomes were immunoisolated using 
A/G paramagnetic beads conjugated to Rab 5, 7, 11 or 14 antibodies. Endocytic 
compartments bound to beads were collected by magnetic separation, digitally imaged 
and then analyzed by HPLC for drug content. Time dependent endocytic uptake was 
observed in all labeled endosomes and the data was used to generate 48 h subcellular 
uptake curves (Figure 3.4A). At 48 h, the maximum nanoATV uptake was 10.6 ± 1.4 
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µg/106 cells in Rab 14 (early recycling endosomes) compartments, followed by 8.3 ± 0.7 
µg/million cells in Rab 11 (late recycling endosomes) compartments. The lowest 
nanoATV concentration was found in Rab 5 compartments, representing early 
endosomes, regardless of HIV-1 infection, which was consistent with the co-localization 
confocal microscopy tests.  
3.4.7. Simulation of nanoATV at the subcellular level 
Mathematical means to simulate drug particle uptake and retention at both the cellular 
and subcellular levels were developed based upon our results. These models 
demonstrated that trafficking of nanoformulated particles in endosomal cell 
compartments provided an accurate and reliable view of their behavior in real time. The 
drug levels in specific compartments at different time points together with the 
confirmation that more nanoATV than native ATV could accumulate in late and recycling 
endosomes proved these to be the major subcellular depots for nanoATV. The modeled 
flow of nanoparticles is presented in Figure 3.4C where outside of the cell and the 
specific subcellular compartments involved in trafficking of the majority of nanoATV are 
represented as the graph nodes: ‘Out’ – the outside of the cell, ‘Rab5’, ‘Rab7’, ‘Rab11’, 
and ‘Rab14’ – denoting the compartments identified by the respective Rab proteins. The 
instantaneous concentration of nanoATV outside the cell, Q1, is associated with the node 
‘Out’, and the instantaneous concentrations of respective Rab proteins, Q2, …, Q5, are 
associated with the nodes ‘Rab5’, ‘Rab7’, ‘Rab11’, and ‘Rab14’. It has been noticed that 
the total number of the observed nanoATV/fluorescent labeled particles in the 
experiment decreases over time. This has been taken to account in the model as an 
open path marked δ in the graph of Figure 3.4C. 
    Based on the graph topology, the time changes of the concentrations in the model are 
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where ΔT denotes the time increment in simulations, and (·)(j) denotes the value of (·) at 
jth step of simulation.  
    Based on the experimental results, using multiple linear regression, and curve fitting 
methods implemented as standard MATLAB functions, the following relationships 
between the concentrations Q1, …, Q5, and the rates of changes V1, …, V8 were 
established: 
𝑉! = 0.04269𝑄! + 0.7778 
𝑉! = 0.1000𝑄! − 0.085𝑄! + 0.0814 
𝑉! = 0.0367𝑄! − 0.2714𝑄! + 2.238 
𝑉! = 0.003𝑄! + 0.0367𝑄! − 0.155𝑄! − 0.1263𝑄! + 0.7366 
𝑉! = −0.003𝑄! + 0.155𝑄! − 0.33 
𝑉! = −0.0031𝑄! + 0.2344𝑄! − 0.22 
𝑉! = −0.0031𝑄! + 0.01785𝑄! − 0.112 
𝑉! = 0.01exp (0.01𝑡)𝑄! 
where t is time from the experiment start. The units for all the rates are µg/106 cells/h and 
µg/106 cells for concentrations. The simulation model based on the set of difference 
equations was implemented in MATLAB using similar technique as applied in [97].  
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3.4.8. Subcellular antiretroviral activity 
To determine in which compartments the virus persists and the antiretroviral efficacy of 
our nanoATV at a subcellular level, MDMs were challenged with HIV-1ADA for 4 h at a 
MOI of 0.1, then treated with 100 µM native ATV or nanoATV for 16 h. MDM were 
mechanically disrupted at days 7 and 14, and subcellular compartments were 
immunoisolated using A/G paramagnetic beads conjugated to Rab 5, 7, 11 or 14 
antibodies. Endocytic compartments bound to beads were collected by magnetic 
separation for the RT assay. The highest RT activity was found in Rab 11 
compartments, representing recycling endosomes, and Rab 7 compartments, 
representing late endosomes, in non-treated cells after 7 and 14 days of HIV-1 challenge 
(Figure 3.5B), respectively, which suggested that virus located mainly in these 
endosomal compartments. NanoATV and native ATV at 100 µM both exhibited 
antiretroviral efficacy, while nanoATV more effectively decreased RT activity in all 
endosome compartments, especially Rab 7 and 11 fractions. Based on the confocal 
results, greater overlap of nanoATV and cellular compartments was found in late and 
recycling endosomes, which could explain why nanoATV was more effective in 
suppressing HIV-1 virus in these compartments. 
3.5. Discussion 
Nanocrystals are broadly used for drug delivery due to their high drug loading capacity, 
increased dissolution in solution and enhanced bioavailability [98-101]. Herein, we report 
the manufacture of P407 coated nanocrystal ATV (nanoATV) by homogenization and 
show that its physical properties, including size and surface charge, facilitate 
macrophage particle uptake and drug stability. Indeed, nanoATV was readily internalized 
by macrophages and produced sustained drug release. This serves to improve drug 
 67 
efficacy by increasing subcellular bioavailability. Nanosized drug crystals coated with 
surfactant exhibit enhanced cellular uptake and facilitate the cellular maintenance of 
drug particles for prolonged time periods. Particle coating serves to increase intracellular 
drug stability. Notably, nanoATV leads to effective inhibition of HIV-1 replication for 
prolonged time periods. In contrast to native ATV, nanoATV shows weeks of viral 
suppression linked to its abilities to increase drug delivery to subcellular macrophage 
compartments. This is facilitated by sustained antiretroviral drug release rates.  
     Interestingly, HIV-1 infection affects the size and or number of endosomes as 
reflective of Rab protein expression (G. Zhang, preliminary communication). We posit 
that such virus-induced alterations in endosomes are biologically relevant to sustain viral 
growth.  Indeed, endosomes are sites of active viral assembly and are the cellular 
substructures where large numbers of virions accumulate during productive infection 
[89].  Such a function has added strategic advantages for the nanoformulated 
antiretroviral drug as it enables the drug particle to reside in the identical site where viral 
maturation occurs in the cell. Taken together, such events certainly facilitate 
antiretroviral drug activities. This may also be operative for a broad number of 
endosomal compartments that affect “transport” of anti-microbial drugs and is likely a 
common pathway for macrophage scavenging functions. Notwithstanding we also 
accept that the pathways for endosomal trafficking and HIV are not perfectly congruent. 
Further investigations will determine the mechanisms behind each trafficking scheme. 
Such observations, nonetheless, open the means to improve antimicrobial therapies 
beyond what is being reported in the current study.  
     Over the past decade our laboratory has pioneered the development of long-acting 
nanoART. NanoATV serves as a model for macrophage-based nanoparticle drug 
delivery as descriptions of cell uptake and intracellular localization of ART content 
parallel one another. To better understand formulation trafficking at the cellular and 
 68 
subcellular levels, we developed a mathematical means to simulate endosomal 
trafficking [90]. The model is simple to implement and can provide assessment of 
“putative” drug activities based on changes in concentration of nanoATV and/or Rab 
proteins in real time. Based on the model, divergent behaviors between native and 
nanoATV were readily observed. NanoATV was taken up efficiently into macrophages 
and effected sustained drug release while native ATV was minimally internalized. This 
helps to explain why nanoATV possesses distinct long-acting antiretroviral efficacy. 
Through our subcellular uptake simulation model, nanoATV subcellular distributions 
were visualized, and late and recycling endosomes were considered as the nanoATV 
depots. Indeed, large amounts of nanoATV were deposited in these endocytic 
compartments. However, it is also noted that differences exist between HIV-1 and 
nanoparticle drug subcellular accumulation including recycling endosomes. Whether this 
is a clever means of virus altering the “transport” properties of nanoparticles or a 
compensatory host mechanism in attempts to contain virus is not yet known.  Further 
studies are certainly needed to assess the unique transport properties of the virus and 
the drug-laden particle.  
     Harnessing macrophage transport properties for drug delivery can improve clinical 
drug responses. Indeed, cell-based nanocarriers have been developed for not only 
cancer chemotherapy but also a wide range of microbial infections [102-104]. 
Macrophage-based nanomedicine delivery schemes may have several advantages over 
more conventional drug delivery including enhanced cure rates, reduced side effects, 
increased drug stability and effective subcellular targeting [28, 95, 105, 106]. Using the 
macrophages as a nanocarriage vehicle can permit investigations of nanoATV entry, 
intracellular trafficking and drug release kinetics.  
       NanoATV contained within endocytic compartments provide a protected 
environment to facilitate drug release with unaltered antiretroviral activities. Both late and 
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recycling endosomes were able to retain a large number of the nanoparticles. 
Macrophages likely play a vital role in HIV pathogenesis as they are among the first cells 
infected [107, 108]. Within an infected macrophage, virions are formed in a temporally 
and spatially coordinated manner wherein the components that make up the virus 
assemble in association with a specific cellular membrane from which the viral envelope 
is derived [89]. HIV-1 virions bud directly into late endosomes and thereby acquire late 
endosomal membrane proteins, such as Rab 7, LAMP-1 and CD63 [88]. Macrophages 
secrete virions from virus-containing intracellular vacuoles [109]. Late endosomes are 
principal locales for HIV assembly [110-114]. Importantly, nanoATV retains full 
antiretroviral activity in late endosomes, as RT activity was significantly decreased in 
Rab 7 and Rab 11 vesicles.  
      In summary our results demonstrate that nanoATV and HIV target overlapping 
subcellular compartments. Entry of virus and particles inside macrophages tis facilitated 
through clathrin-mediated pathways [115-118]. NanoATV particles are stored within late 
endosomes or recycling compartments, which serves to minimize intracellular 
degradation. For release, nanoATV are slowly recycled to the plasma membrane [119-
122]. This provides a means for escape from phagolysosomal degradation and effective 
delivery of drug to action sites, which in the end has a net effect of improved therapeutic 
efficacy. 
3.6. Conclusions 
NanoATV is now demonstrated to effect increases in cellular drug uptake and retention 
in macrophages. The long acting antiretroviral efficacy of crystalline nanoformulated 
drugs is significantly enhanced over its native counterparts. Macrophages act as carriers 
of nanoATV to improve drug bioavailability. Computer assisted mathematical modeling 
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can simulate subcellular trafficking of nanoATV to late and recycling endosomes that 
serve as drug particle depots. Overall, nanoATV and HIV utilize similar subcellular 








Figure 3.1. Comparisons of native and nanoATV cellular drug uptake and 
antiretroviral activity.  
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(A) Time course for monocyte-derived macrophage (MDM) uptake of native or nanoATV 
are illustrated. MDM cultures were treated with native or nanoATV for 24 h. (B) 
Computational simulation of the time course of MDM drug uptake and retention. After 24 
h treatment with native or nanoATV, cells were washed with PBS and treated with fresh 
medium for 24 h. HIV-1 (C) DNA and (D) RNA levels were quantitated 14 days after 
infection in MDM treated with various concentrations of native or nanoATV. The units for 
viral DNA and RNA are copies/103 cells and copies/cell, separately. HIV reverse 
transcriptase (RT) activity 14 days after HIV-1 infection in MDM treated with various 
concentrations of (E) native- or (F) nanoATV. Data are expressed as average +/- SEM 




Figure 3.2. HIV-1p24 staining of virus-infected MDM pre-treated with native or 
nanoATV.  
MDM were treated with native or nanoATV for 16 h then challenged with HIV-1 at a MOI 
of 0.1.  Infection was allowed to continue for 14 days. The treatment groups included: (A) 
HIV-1 infected controls; (B-D) 1, 10 and 100 µM native ATV, respectively; (E-G) 1, 10 





Figure 3.3. NanoATV subcellular distribution. 
 (A) Uninfected MDM and (B) HIV-1  infected MDM were treated with 100 µM, dye-
labeled nanoATV for 16 h then immunostained with Rab 5, 7, 11 or 14 antibodies and 
AlexaFluor 488-labeled secondary antibody (green) to visualize particle and organelle 
co-registration. Quantitation of the overlap of nanoATV and Rab proteins in (C) 
uninfected and (D) HIV-1 infected MDM are shown. Data are expressed as the average 






Figure 3.4. Kinetics of particle trafficking in subcellular endosomes.  
(A) Subcellular uptake in different compartments in MDM treated with 100 µM nanoATV 
over 48 h. (B) Simulated subcellular nanoATV uptake activity in different compartments 
over the same time frame. (C) Simulated subcellular nanoATV uptake pathways. Data 





Figure 3.5. Intracellular pathways for HIV-1 progeny virion production and 
nanoATV trafficking.  
(A) Schematic diagram for HIV-1 and nanoATV trafficking. HIV reverse transcriptase (RT) 
activity in subcellular endosomal compartments is shown. MDM were infected with HIV-1 
for 4 h then treated with 100 µM native or nanoATV for 16 h. Endosomal compartments 
were isolated using specific Rab antibody-coated magnetic beads and RT activity was 
measured in endosomal compartments on (B) day 7 and (C) day 14 after infection. R5, 
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Opposing regulation of 
endolysosomal pathways by 
long-acting nanoformulated 




Long-acting nanoformulated antiretroviral therapy (nanoART) is designed to improve 
subject regimen adherence, reduce systemic drug toxicities, and facilitate clearance of 
human immunodeficiency virus type one (HIV-1) infections. While nanoART establishes 
drug depots within recycling and late monocyte-macrophage endosomes, whether or not 
this provides a strategic advantage to eliminate the virus is not been completely 
elucidated. To this end, we applied quantitative SWATH-MS proteomics and cell profiling 
to nanoparticle atazanavir (nanoATV)-treated and HIV-1 infected human monocyte-
derived macrophages (MDM). Native ATV and uninfected cells served as controls. 
Surprisingly, both HIV-1 and nanoATV engaged the endolysosomal trafficking for their 
assembly and depot formation, respectively. Notably, the pathways were deregulated in 
opposing manners by the virus and the nanoATV likely by viral clearance. Paired-sample 
z-scores, of the proteomic data sets, showed up- and down- regulation of Rab-linked 
endolysosomal proteins. NanoART and native ATV treated uninfected cells showed 
limited effects. The data was confirmed by Western blot. DAVID and KEGG 
bioinformatics tools showed relationships between secretory, mobility and phagocytic 
cell cell functions and virus and particle trafficking. We posit that modulation of 
endolysosomal pathways by antiretroviral nanoparticles provides strategic path to 
combat HIV infection.    
4.2. Introduction  
Long acting nanoformulated antiretroviral therapy (nanoART) is emerging as an 
important part of the treatment armamentarium for human immunodeficiency virus type 
one (HIV-1) infection [123-126]. While our prior studies defined both a platform for drug 
delivery and the trafficking mechanisms operative for nanoART in monocyte-
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macrophages, how these cells can be harnessed as drug depots for improved 
antiretroviral responses has not been realized [55, 62, 63, 95, 127]. Indeed, human 
monocyte-derived macrophages (MDM) serve as nanoART carriers extending ART half-
life and drug stability [35, 81]. Such cell-based drug delivery strategies may also 
decrease systemic drug toxicities [53, 128]. We posit that endolysosomal pathways can 
serve as Trojan horses for viral persistence or as vehicles for its elimination. If correct, 
facilitated viral replication and the means to eliminate it may occur at identical subcellular 
locales. The operative nanoART response would facilitate drug delivery by bringing the 
medicine to the site of action within mononuclear phagocytes (MP; monocytes, 
macrophages and dendritic cells). To investigate a seemingly mechanistic paradox, 
functional proteomic tests were employed to uncover how drug particles affect the HIV-1 
replication cycle beyond nanoART activity.  
The intracellular trafficking pathways held by the virus and nanoART were investigated 
by Sequential Windowed data independent Acquisition of the Total High-resolution Mass 
Spectra (SWATH-MS) profiling. This technique was applied to obtain a broader picture 
of complex nanoART-HIV interactions. The method was previously employed in our and 
other laboratories to identify and quantify cellular peptides on a larger scale [129-133]. 
While past transcriptomic and proteomic analyses were applied to study virus-cell 
interactions [130-133], they have failed to uncover key proteins affected by targeted 
antiretroviral treatments. Herein, we identified deregulated cellular proteins affected by 
nanoatazanavir (nanoATV) in HIV-1-infected MDM. Comparison was made between 
formulated and native ATV by the effect of HIV-1. Common cellular proteins with 
coordinated molecular, biochemical and biological functions were altered in virus-
infected and nanoATV treated cells. These were linked to phagosome signalling 
pathways specifically associated with the endosomal and lysosomal compartments. 
Specifically, opposing expressions of Rab7 and -11 and LAMP1 were seen in HIV-1 
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infected and nanoATV-treated cells. Notably, the downregulation of late and recycling 
endosomes and LAMP1, indicated that pathways that could be employed, in measure, 
for viral assembly and nanoparticle lysosomal degradation were affected. Through cross 
validation of proteomics, cell biology and protein chemistry, our data provide novel 
insights into how nanoART facilitates viral clearance while establishing long-lived cell-
based depots different from native drug. These works represent a previously unknown 
mechanism for how long-acting nanoART provides a strategic advantage to combat viral 
infection.  
4.3. Materials and methods 
4.3.1. Reagents and Antibodies  
ATV sulfate (Gyma Laboratories of America Inc., Westbury, NY, USA) was free based 
with triethylamine. Poloxamer 407 (P407) and CF568-succinimidyl ester (CF568) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Human serum was obtained from 
Innovative Biologics (Herndon, VA, USA). Macrophage colony-stimulating factor (MCSF) 
was prepared from 5/9m alpha3-18 cells (ATCC; CRL-10154) [54]. Rabbit anti-human 
Rab 5, -7, -11, LAMP1 and β-actin antibodies were purchased from Santa Cruz 
Biotechnology, Dallas, TX, USA. Alexa Fluor 594 goat anti-rabbit IgG and Alexa Fluor 
647 donkey anti-mouse IgG were obtained from Life Technologies (Eugene, OR, USA) 
4.3.2. NanoATV manufacture and particle characterization  
P407-ATV was prepared by high-pressure homogenization using an Avestin Emulsiflex 
C3 homogenizer (Avestin Inc; Ottawa, ON, Canada) [63, 82]. CF568-labeled P407-ATV 
was prepared as described previously [53] using a 1: 4 (w/w) ratio of CF568-P407 and 
P407. Drug content of the nanosuspensions were determined by reverse phase high-
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performance liquid chromatography (HPLC) [105]. Particle size, polydispersity and zeta 
potential for the nanoparticles were determined by dynamic light scattering using a 
Malvern Zetasizer Nano-ZS instrument (Malvern Instruments Inc.; Westborough, MA, 
USA).  
4.3.3. Monocyte isolation, cultivation and HIV-1 Infection 
Human peripheral blood monocytes were obtained by leukapheresis from HIV-1,2 and 
hepatitis B seronegative donors and plated at a density of 1 x 106 cells/mL in Dulbecco’s 
modified Eagle’s medium supplemented with 10% heat-inactivated human serum, 1% 
glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin and 1,000 U/ml MCSF. After 
seven days of cell differentiation, MDM were infected with HIV-1ADA at a MOI of 0.1 
infectious viral particles per cell. After 4 hours the medium was removed and cells were 
treated with 100 µM P407-ATV. Following 16 hours of drug treatment, the media was 
replaced with drug-free fluids and cells were incubated for an additional seven days [57, 
62].  
4.3.4. SWATH-MS  
MDM samples for mass spectrometry were collected seven days after infection and drug 
treatment. Cells were washed with ice-cold PBS, scraped, pelleted, and stored at −80°C 
until processed. Cell samples from four donors were processed simultaneously. Cell 
pellets were re-suspended in cell lysis buffer containing 4% (w/v) SDS, 0.1 M 
dithiothreitol (DTT) and 0.1 M Tris-HCl. Lysates were vortexed at room temperature for 
10 min and then boiled at 95°C for 5 min to denature proteins. Protein quantification was 
performed using the Pierce 660 nm protein assay (Thermo Scientific; Wilmington, DE, 
USA) following the manufacturer’s protocol. On the basis of protein quantifications, 100-
200 µg of each sample was processed using filter aided sample preparation (FASP) 
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[134-136]. Samples were denatured with urea exchange buffer (8 M urea, 0.1 Tris-HCl, 
pH 8.5) placed into filter cartridges (10 kDa), centrifuged and then treated with 50 mM 
iodoacetamide (Sigma-Aldrich). Trypsin (Promega; Madison, WI, USA) was added (2 
µg/100 µg protein) and incubated at 37°C overnight on the cartridge. Eluted peptides 
were dried via vacuum centrifugation. Peptides were cleaned using an Oasis mixed 
cation exchange cartridge following manufacturer’s protocols (Waters Inc.;  Milford, MA, 
USA) and then dried under vacuum.  After processing through mixed cation exchange, 
peptides were subjected to further clean up using C18 Zip-Tips (EMD Millipore; Billerica, 
MA, USA) and dried under vacuum.  Peptides were resuspended in 0.1% formic acid 
(Honeywell Burdick & Jackson; Muskegon, MI, USA) and quantified using 
NanoDrop2000 (Thermo Scientific).  One µg of peptide was then prepared for SWATH-
MS quantitative proteomics analysis, as previously described [129, 137]. Samples used 
to generate the SWATH-MS spectral library were subjected to traditional, data-
dependent acquisition (DDA).  
4.3.5. Bioinformatics  
Each SWATH-MS condition (per each donor) was transformed independently of other 
conditions and comparisons between control condition and experimental conditions were 
calculated. Extracted raw data transformation was performed as described by Haverland 
et al. [129] The raw intensity for each protein was transformed by taking the natural log 
(ln) of the intensity followed by assignment of z-score. The p-value for the computed z-
score was assigned using standard normal distribution. Functional analysis and 
signalling pathway representation were performed using an array of complementary, 
open-access bioinformatic tools. Functional annotation of the proteins differentially 
expressed was performed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) Bioinformatics Resources (6.7) and the Protein Analysis 
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Through Evolutionary Relationships (PANTHER) Classification System (9.0), by entering 
the UniProt sequence feature. The gene ontology (GO) annotations showed proteins 
according to Biological Processes, Molecular Functions and Cellular Components. 
Protein Class functional analysis was obtained by PANTHER. Protein–protein 
interactions among all identified transcription regulators were investigated using Search 
Tool for the Retrieval of Interacting Genes/Proteins (STRING) (9.1) considering a 
confidence of greater than 0.4 (medium confidence). Unconnected proteins (orphan 
proteins) and unconnected satellite networks (networks which were detached from the 
largest network) were removed. 
The complementary pathway analysis, Kyoto Encyclopedia of Genes and Genomes 
(KEGG) was used to determine significant pathways between experimental conditions. 
The KEGG pathway (71.0) for the phagosome was coloured using the KEGG mapper 
colour pathway tool. Green represents all proteins confidently identified and red and blue 
colours are assigned to up- or down-regulated proteins, respectively.  
4.3.6. Antiretroviral activities 
HIV-1 reverse transcriptase (RT) activity was measured to assess antiretroviral efficacy 
in HIV-1 infected MDM. MDM were treated with 10, 100 or 250 µM native- or nanoATV 
for 16 hours then infected with HIV-1ADA for 4 hours at a MOI of 0.1 immediately and five 
and 10 days after drug treatment. Following viral infection, cells were cultured for an 
additional seven days at which time cell media were collected for measurement of RT 
activity. Briefly, in a 96-well plate, 10 µL of sample supernatants were mixed with 10 µL 
of solution containing 100 mM Tris-HCl (pH 7.9), 300 mM KCl, 100 mM dithiothreitol, 
0.1% NP-40 and water. The reaction mixture was incubated at 37˚C for 15 min and 25 
µL of a solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 5 mM DTT, 15 mM 
MgCl2, 0.05% NP-40, 10 µL/mL poly(A), 0.25 U/mL oligo d(T) and 10 µCi/mL 3H-
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thymidine triphosphate was added to each well; plates were incubated at 37˚C for 18 
hours. Following incubation, 50 µL of cold 10% TCA was added to each well, the wells 
were harvested onto glass microfiber filters and the filters were assessed for 3H-
thymidine triphosphate incorporation by b-scintillation spectroscopy using a TopCount 
NXT (Perkin Elmer Inc.; Waltham, MA, USA) [55, 62]. 
4.3.7. Western Blots 
Protein expressions of Rab 5, 7 and 11, LAMP-1 and Actin were detected by Western 
blot assays. MDM were treated with native drug or nanoATV and infected with HIV-1ADA 
as described. Seven days after infection cells were collected and lysed using CellLytic M 
Cell Lysis Reagent (Sigma-Aldrich). Protein content was quantitated using the Pierce 
660-nm protein assay. Ten µg of protein was separated by electrophoresis using a 
NuPAGE Novex 4-12% Bis-Tris gel (Life Technologies-Novex; Grand Island, NY, USA). 
After electrophoresis, the proteins were transferred to a PVDF membrane (BioRad 
Laboratories, Hercules, CA, USA) and then blocked with 5% non-fat dry milk in PBS and 
0.1% Tween-20 (PBST). Membranes were probed with primary antibodies for Rab5, 
Rab7, Rab11 or LAMP-1 and β-actin (Santa Cruz Biotechnology) followed by 
horseradish peroxidase-conjugated secondary antibody (Life Technologies-Novex). 
Proteins were detected using the SuperSignal West Pico Chemiluminescent substrate kit 
(Thermo Scientific) [55, 81, 138]. 
4.3.8. Immunofluorescence and confocal microscopy 
For immunofluorescence staining, cells were washed three times with PBS and fixed 
with 4% paraformaldehyde (PFA) at room temperature for 30 min. Fixed cells were 
permeabilized with 0.1% Triton in PBS and then blocked with 5% bovine serum albumin 
(BSA) in PBS for 30 min. Cells were washed with 5% BSA in PBS and sequentially 
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incubated with primary antibody against HIV-1 p24 (Dako; Carpinteria, CA, USA) and 
either Rab5, -7, -11 or LAMP-1 (Santa Cruz Biotechnology) for 1 hour then washed 3 
times with PBS. Secondary antibodies conjugated with Alexa594 or Alexa647 dyes (Life 
Technologies-Molecular Probes) were applied against the primary antibody isotype and 
incubated at room temperature for 1 hour then washed 3 times with PBS. Slides were 
covered in ProLong Gold AntiFade reagent with DAPI (Life Technologies-Molecular 
Probes) and imaged using a 40X oil lens on a LSM 510 confocal microscope (Carl Zeiss 
Microimaging, Inc.; Dublin, CA, USA) [55, 139]. 
4.3.9. Cytokine Bead Array 
MDM were infected with HIV-1ADA for 4 hours at a MOI of 0.1 then treated with 100 µM 
native- or nanoATV for 16 hours immediately. 24 hours after drug treatment, 50 µL cell 
culture media from treated and infected MDM were tested to determine the 
concentrations of inflammatory cytokines measured by a cytokine bead array (CBA) 
detection kit (Becton Dickinson Biosciences; Mississauga, ON, USA) and performed 
according to instructions of the manufacturer. Monoclonal antibodies specific to 
interleukin-12 (IL-12), tumor necrosis factor (TNF), IL-10, IL-6, IL-1b and IL-8 were 
added to the samples in a 96 well plate. A serial dilution of known cytokines generated 
the standard curve. Following three hours of incubation, all samples were acquired and 
analysed on a FACSArray. The standard curve was determined using a parameter 
logistics model and analysed with FCAP Array software. Cytokine levels are expressed 
as pg/mL [140]. 
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4.4. Results 
4.4.1. Proteomics analyses of HIV-1 infected MDM  
HIV-1 infection engages a spectrum of cellular proteins seen in specialized cell 
populations that support its replication [109]. The effect of nanoART on cell protein 
expression has not yet been defined, in its target macrophage. To such ends, we applied 
quantitative SWATH-MS proteomics followed by bioinformatics to uncover proteins 
deregulated by free ATV or nanoATV with or without HIV-1 cell exposures. For these 
experiments MDM were first infected with HIV-1ADA and four hours later medium was 
removed and cells were treated with 100 µM P407-ATV. Following 16 hours of drug 
treatment, the media was replaced with drug-free fluids and cells harvested for 
proteomic tests after an additional seven days This experimental paradigm was followed 
to assess the role that the antiretroviral delivery system had on macrophage proteome 
during spreading viral infection. In attempts to separate the effects of the antiretroviral 
drug, the nanoparticle and viral infection both separate and combined analyses of each 
of these were required. Following biological assessments, cells samples were collected 
and we assessed how nanoATV and free ATV could modulate virus-induced protein 
changes. MDM were infected with HIV-1 at a multiplicity of infection (MOI) of 0.1 then 
treated with 100 µM free or nanoATV. After seven days, cells were harvested and 
SWATH-MS was performed on whole cell lysates [129]. Based on the expansive 
proteomic data sets based on the biological response variables amongst the cell 
treatments for nanoATV, ATV and HIV-1 illustrations of the data sets were divided into 
replicate files and two independent figures. The first identified differnces between HIV-1 
infected with or without nanoART and the second (with and without native ATV. 
Quantitative profiling identified 527 significantly changed MDM proteins following HIV-1 
infection.  These were up- or down-regulated (p<0.05) assessed by paired-samples z-
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scores. The numbers of proteins exhibiting changed expression in HIV-1-infected cells 
were greater than in replicate infected cells treated with nanoATV, 527 versus 376 
respectively (Figure 4.1A). Up- and down- regulated proteins in HIV-1 infected cells were 
41 and 59% of total (n=216 and 311, respectively). In contrast for nanoATV-treated HIV-
1-infected MDM, up- and down-regulated proteins were 59 and 41% of total (n=222 and 
154, respectively). Uninfected cells treated with nanoATV had fewer deregulated 
proteins (n=195) compared to the other groups. The proteins uncovered engaged the 
PANTHER database which sorted the deregulated proteins by classes. This illustrated 
the relative numbers of proteins in each class for the HIV-1-infected and infected and 
nanoATV-treated cells (Figure 4.1B). This showed that the number of deregulated 
proteins in HIV-1-infected versus infected and nanoATV-treated cells was greater for 
each of classes (nucleic acid binding, hydrolase, transferase, protease, signalling 
molecule, transporter, transcription factors and ligases). These results demonstrate that 
the deregulation of cellular proteins by HIV-1 infection can be altered by nanoATV 
treatment. To uncover the function classes of proteins deregulated by HIV infection we 
examined the functional categories by PANTHER classification. These data are based 
on Gene Ontology annotations (GO molecular function, GO biological processes and 
GO cellular component). Figure 4.2A shows the proteins sorted according to molecular 
function with the percentages of total deregulated proteins classified for subgroups. 
Common proteins were separated based on binding (28 to 31%), enzyme regulator (5%) 
and transporter (3-4%) activities between the nanoATV, HIV-1 and HIV-1 and nanoATV 
MDM. Proteins included Rab5, 7 (GDP/GTP and protein binding) and LAMP1 (enzyme 
and protein binding) were joined. The classification revealed enrichment for metabolic, 
cellular, localization, regulation and cellular organizational cellular processes. These 
were the principal categories or protein sets (Figure 4.2B). The relative ratios for the 
proteins were similar amongst groups. GO for cellular component showed that 
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deregulated proteins sorted by cell organelle and macromolecular complex (Figure 
4.2C). Note that such groupings were common to HIV-1 and HIV-1 and nanoATV cells. 
The data, demonstrated that HIV-1 and HIV-1 and nanoATV affect similar cellular 
processes. However, the numbers of proteins in each were reduced following infection 
and nanoATV treatment.   
4.4.2. KEGG pathway analyses for HIV-infected MDM 
The proteins relative to functional pathways were further investigated using the KEGG 
database, which, indicated phagosomes as one of the main pathways related to HIV-1 
infection and nanoATV treatment. First we identified the role of HIV-1 infection as 
compared to HIV-1 infected nanoART-treated MDM on the phagosome network (Figure 
4.3A and B, respectively). Few numbers of proteins were deregulated with nanoATV 
treatment. However, proteins were deregulated during HIV-1 infection and treatment 
groups.  Notably, there was an opposite regulation for proteins within the phagosome 
and endosomal compartment between HIV-1-infected and HIV-1-infected and nanoATV-
treated MDM. Up-regulation of Rab 5 and -7 proteins was observed in HIV-1 infected 
cells; in contrast these same proteins were down-regulated in nanoATV-treated HIV-1 
infected cells, pink = increased expression, blue = decreased expression). A similar 
pattern for LAMP1 was also observed. Moreover, DAVID functional enrichment 
clustering gave similar enrichment results for lysosomes in HIV-1-infected and HIV-1-
infected and nanoATV-treated cells by filtering the data sets at a P value <0.01. There 
was a down-regulation of endosomal and lysosomal proteins in the group of uninfected 
cells treated with native ATV (Figure 4.4A) or nanoATV. The latter showed few down-
regulated in parallel endosomal compartments (Figure 4.4B). HIV-1 infected MDM 
treated with native ATV showed few altered proteins (data not shown).  A composite of 
these protein network changes are summarized in Table 4.1.  
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4.4.3. Protein-protein interaction networks  
To elucidate the operative and dynamic biological processes, methods depicting 
changes of protein interaction networks are needed. Here we used our data from 
SWATH-MS and applied it to the STRING bioinformatics tool to determine the dynamics 
of the protein interaction after HIV-1-infection with or without nanoATV treatment. 
Differentially expressed proteins in infected or infected and treated MDM were identified 
using a P-value <0.05, and protein-protein interaction [141] networks were constructed. 
The results of the networking reproduced a consistently high number of altered cellular 
proteins by HIV-1 (Figure 4.5A). The complex changes and interactions during HIV-1 
infection are clearly visualized and, more importantly, the reduced complexity is clear 
when the infected cells are treated with nanoATV (Figure 4.5B). These dynamic changes 
following HIV-1 infection and nanoATV treatment provide evidence of the importance of 
antiretroviral therapy to control protein-protein interaction networks. 
4.4.4. Antiretroviral activities of native and nanoformulated ATV 
To confirm the antiretroviral activity of the nanoATV treatment the HIV-1 RT activity was 
determined in native- or nanoATV-treated HIV-1-infected MDM. Cells were treated with 
10,100 or 250 µM of native drug or nanoATV for 16 hours, followed by HIV-1ADA 
challenge at an MOI of 0.1 at days 0, 5 and 10 after treatment. Infected cells were 
cultured for an additional 7 days and RT activity in the culture medium was determined. 
Significant differences were found between cells treated with native- or nanoATV. For 
native ATV treated cells, RT activity was suppressed only in the day 0 infection group, at 
all treatment concentrations. At 10 and 100 µM little antiviral suppression was observed 
in the day 5 and 10 infection groups. In contrast, for cells treated with nanoATV, RT 
activity was suppressed to less than 20% HIV-1 positive control with all treatment 
concentrations and at all infection days (Figure 4.6) 
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4.4.5. Endolysosomal proteins deregulated HIV-1 and nanoATV  
We selected the proteins from the KEGG pathway related to phagosome and endosomal 
compartment which were oppositely regulated by HIV-1 and HIV-1/nanoATV, (Rab 5, -7, 
-11 and LAMP 1), for validation of the proteomics analysis. Protein expression of Rab 5, 
-7, -11 and LAMP1 was determined by Western blot. As shown in Figure 4.7, there was 
a down-regulation in Rab 5, -7, -11 and LAMP1 protein expression in nanoATV-treated 
infected cells group. This effect was greater than that seen with native ATV treatment, 
validating the KEGG analyses, and was time dependent, highlighting the dynamic nature 
of endosomal trafficking based on macrophage differentiation, viral infection and 
nanoparticle treatments. Notably, assay of Rab protein levels, at multiple days following 
of HIV-1 infection and antiretroviral treatment revealed that nanoATV while inducing a 
significant down-regulation of endosomal and lysosomal proteins the effects paralleled 
what was observed in uninfected cells. Moreover, the downregulation was significant as 
it was sustained over 10 days. To better assess the potential relationships between the 
virus, Rab protein and nanoART we used immunofluorescence to visualize if co-
localization of Rab7 or LAMP1, HIV-1 p24 and nanoATV could occur. 
Immunofluorescence co-localization (Figure 4.8) demonstrated that HIV-1 p24 (yellow), 
Rab7 or LAMP1 cellular proteins and nanoATV were in the identical cellular locale. 
These results highlight the fact that the endosomal trafficking routes taken by the virus 
and the nanoparticles are identical. Most importantly the results support the idea that 
HIV-1 and nanoATV while present in the identical subcellular locale influence endosomal 
trafficking in opposite ways.   
4.4.6. Cytokine profile for HIV-1 and nanoATV 
      To assess the activation state of the MDM, cytokine production was determined in 
HIV-1 infected cells with or without nanoATV treatment. Cell culture media from 
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nanoATV treated and untreated HIV-1 infected and uninfected MDM were incubated with 
capture beads for IL-12, TNF, IL-10, IL-6, IL-1b and IL-8 and a detection fluorochromo. 
Acquisition was performed by FACSArray cytometry. IL-12 and TNF were increased in 
HIV-1 infected MDM. However, when the infected cells were treated with nanoATV 
cytokine levels were reduced (Figure 4.9), implying a positive correlation with endosomal 
and lysosomal proteins expression in our analysis mentioned above. NanoATV treated 
infected macrophages also expressed higher levels of IL-6 and IL-8, compared to 
infected and uninfected cells. There were no significant changes for IL-10 and IL-1b 
(data not shown). These results showed a negative correlation in the expression of IL-12 
and TNF between treated and untreated HIV-1 infected MDM, suggesting a role for 
nanoATV as a regulator of pro-inflammatory cytokines. 
4.5. Discussion 
While it is well known that HIV-1 alters cellular nucleic acid binding and regulatory 
protein functions affecting its transcription and translation [129, 142-144] how such virus-
host cell interactions are altered by nanoART is not understood [81]. To this end, we 
used functional proteomics, cell biology and protein chemistry to investigate potential 
interactions between the virus, the host cell and nanoART to elucidate how common 
endocytic trafficking pathways can be engaged to both support viral replication and, at 
the same time, affect its elimination. Endolysosomal pathways were uncovered and 
found to be antagonistic in HIV-1 infected cells with nanoATV treatment. Notably, the 
results highlight how the cell can be manipulated to either facilitate or inhibit viral growth.  
The data also serves to highlight unique cellular processes engaged in both the viral 
replication cycle and the means to attenuate it. Within an infected cell, virions are formed 
in association with the cellular membrane. Initial investigations of HIV-1 assembly in 
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macrophages were done through electron microscopy studies and suggested that new 
virions were formed from the limiting membrane of a late endosomal compartment that 
was linked to vesicle formations as is known to occur in multi-vesicular bodies (MVB) but 
not at the plasma membrane known to be operative in T cells [113]. The linkage 
between Endosomal Sorting Complex Required for Transport (ESCRT), MVB biogenesis 
and viral budding is well known. In past years it was thought that HIV-1 budding is linked 
to ESCRT through the presence of late endosomal markers associated with 
macrophage-derived virions. However, the model has now been re-examined with 
several recent reports show that the viral compartment has a neutral pH and can be 
connected to the plasma membrane by micro-channels. [145-150]. We posit that the 
virion trafficking and viral budding can be two independent but not mutually exclusive 
pathways.  Both are likely operative. First, we now show through cross validations of 
proteomic, cell biology and protein chemistry is that the endolysosomal machinery is 
significantly deregulated by HIV-1 infection and in opposite manner by nanoART 
treatment. Second, there is a close association between endosomal-linked pathways 
that include Rab5, -7 and -11 and viral infection.  Third, the fact that this pathway is 
conversely down regulated by HIV-1 infection likely reflects that the ability of the virus to 
hijack ESCRT is augmented by the drug nanoparticles.  Such a theory was previously 
put forward in our own past works [81].  In regards to assembly and intracellular 
accumulation of progeny HIV-1 we need not discount the elegant work performed by 
immunofluorescence microscopy and immunoelectron microscopy that the organelles 
are of an internally sequestered plasma membrane domain divergent from endosomes. 
Both pathways can be operative in this scenario and are not mutually exclusive from one 
another. Nonetheless, there is little question that virions are endosomal-associated. 
Progeny virions are pulled down associated with these proteins and reverse 
transcriptase activities are reduced significantly in parallel structures. While we did not 
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study the tetraspanins CD81, CD9, and CD53, their regulation in phagocytosis or 
intracellular trafficking is appreciated [151]. It is noted that CD81 is linked to activation of 
mononuclear phagocytes, notably microglia [152]. Moreover, they are also involved in 
the formulation of multinucleated giant cells [153] an additional major feature of viral 
infection in macrophages. Rab proteins function to evade degradation and direct 
transport to intracellular locations and utilize host vesicles to affect a stable intracellular 
niche for microbial stability and longevity [154]. Thus, it is not surprising that HIV-1 would 
induce these pathways. While the uninfected macrophages, the proteins are at the cell 
surface and in intracellular vacuole-like structures with a complex content of vesicles and 
interconnected membranes these compartments are in a dynamic state within the cell 
and strongly regulated by HIV-1. While we acknowledge that endosome markers could 
be recruited to the viral structures and incorporated into virions the dynamic process of 
the virus and the macrophage transcends progeny virion assembly and includes viral 
trafficking and transport mechanisms. Such observations combined with a broader 
theory of the complexity of virus-cell interactions in the infected macrophages heralds 
the notion that multiple events are operative for virion assembly and persistence [155].  
NanoART enters the macrophages primarily through clathrin-mediated pathways 
and is then stored in endocytic compartments. This provides a protected environment for 
release of the drug to sites of viral growth. Compared with nanoART, the non-fromulated 
native drug didn’t show similar trafficking behavior since less endolysosomal proteins 
were found related to native drug treatment. On the one hand, amorphous native drug 
can hardly be taken or stored by macrophage; on the other hand, native drug cannot be 
internalized or carried by subcellular compartments for intracellular transportation. 
Subcellular distribution of nanoformulated ART is in late and recycling endosomal 
compartments. These same compartments serve as drug depots. Since late endosomes 
 96 
are sites of viral assembly, nanoART stored within such compartments can retain 
significant antiretroviral activity. This was clearly demonstrated by the significant 
reductions in HIV-1 RT activity previously observed in isolated endosomal compartments 
in nanoATV treated HIV-1 infected MDM. 
All together, the current studies suggest a mechanism whereby the endolysosomal 
pathway is harnessed for HIV-1 viral replication and this same pathway may provide a 
means for its elimination. Indeed, while it is known that HIV-1 traffics through Rab5, -7, 
and -11 endosomal compartments how such early, late, and recycling endosomal pools 
regulate stages of the viral life cycle are not understood [156]. Such an intersection 
though is believed critical to the viral life cycle as the functions of the compartments 
serve to maintain cell homeostasis and protein transport [157]. It has been reported that 
Rab5 regulates clathrin-mediated endocytosis from the plasma membrane to early 
endosome pools serve as an intersection point for proteins sorted to undergo 
degradation through Rab7-dependent late endosome and lysosomal routes or be sorted 
back to the plasma membrane through Rab11-dependent recycling pathways [156]. The 
ability of the macrophage to overcome such degradation events at the subcellular level 
underlie its abilities to persistent in its macrophage reservoir [156]. Moreover, it is well 
known and accepted that Rab proteins function to evade degradation and direct 
transport to intracellular locations and utilize host vesicles to affect a stable intracellular 
niche for microbial stability and longevity. Similar mechanisms certainly parallel the 
persistence of nanoART and sustained drug depots for extended time periods. Notably, 
while proteomic tests revealed a large number of proteins deregulated by HIV-1 infection 
and these were the same protein sets also affected by nanoART. The protein sets 
included those affecting nucleic acid binding, hydrolase and enzyme activities, 
oxidoreductase responses, and the cellular cytoskeletal backbone. These were all 
characterized by GO molecular function that placed Rab5 and -7 proteins as those 
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engaged in GTP catabolic processes, endocytosis and small GTPase-mediated signal 
transduction pathways. The molecular functions for both endosomal-linked proteins are 
GDP/GTPase activity and protein binding [158]. LAMP1 is associated with autophagy, 
the establishment of protein localization to cell organelles, golgi to lysosome transport, 
protein transport along microtubules and regulation of natural killer cell degranulation 
cytotoxic activities. For the cellular component GO classification, LAMP1 is located at 
the late endosome, lysosome, multivesicular body and vesicular exosome. It is included 
in the group of enzyme and protein binding molecular function protein sets. Indeed, as 
GO information, Rab family members are small, RAS-related GTP-binding proteins that 
regulate vesicular transport. Each Rab targets multiple proteins that act in exocytic and 
endocytic pathways.  
An important finding in the current study was that Rab5, -7 and -11 and LAMP1 
were significantly upregulated in expression following HIV-1 infection. HIV-1 could 
induce those proteins linked to endosomes. While endosome markers could be recruited 
to the viral structures and incorporated into virions the dynamic process of the virus and 
the macrophage transcends progeny virion assembly but also viral trafficking and 
transport mechanisms also strongly affected during the dynamic course of viral infection. 
Interestingly, Rab 5, -7, -11 and LAMP1 deregulation in infected MDM was reversed, in 
part, by nanoATV. The extent of protein deregulation in infected MDM was reduced by 
nanoATV. As shown in some studies, Rab5 has a role in endocytosis and post-endocytic 
trafficking [159]. Its activation promotes focal adhesion disassembly, migration and 
invasiveness in tumor cells [160] and its knockdown decreases cell motility and invasion 
by an integrin-mediated signaling pathway [161]. Moreover, it has been indicated that 
Rab5, -7 and -11, affect RGS4 trafficking through plasma membrane recycling or 
endosomes [158] and are used by the drug particles and the virus in a coordinated 
manner. This was seen for other viral infections such as hepatitis B virus, which can 
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affect Rab5 and -7 expression and use pathways for viral transport from early to mature 
endosomes. This is a required step in the viral life cycle [162]. Similarly, in our study, 
following endocytosis HIV-1 travels through the complex endocytic pathway networks to 
reach the nucleus and initiate its replication and as such support the notion that 
endosomal proteins play a critical role in the viral life cycle.  
 
Interestingly, Rab5, -7 and -11 and LAMP1 were down-regulated in HIV-1 and 
nanoATV-treated cells. This opposite regulation between HIV-1 and nanoATV in 
regulation of endosomal proteins is likely important in that cellular trafficking pathways 
and may also be involved in the release of infectious progeny virus.  As such late 
endosome-associated Rab7A is known to be required for HIV-1 propagation, regulation 
of Env processing and the incorporation of mature Env glycoproteins into viral particle 
[163]. In addition Rab7A promotes Vpu interaction with BST2/tetherin to facilitate HIV-1 
release [164]. This may also be operative for nanoparticle viral interactions and suggests 
that in the present study nanoATV may disrupt mechanisms of critical cellular protein-
protein interactions harnessed during the viral life cycles to perpetuate its growth. In 
other studies, silencing the expression of Rab9 inhibited HIV-replication [141] and 
silencing the endogenous Rab11a GTPase expression could destabilize HIV-1 Gag and 
reduce virion production both in vitro and in NOD/SCID/gc-/- mice [165]. It has been well 
documented that Rab11 is located on pericentriolar recycling endosomes and plays a 
key role in regulating vesicle trafficking through recycling endosomes to the plasma 
membrane as well as in exocytosis [81, 114, 166]. Therefore, down regulation of Rab11, 
as shown in our study, could destabilize HIV-1 proteins that would fail to traffic through 




The deregulation of endosomal proteins suggests a new mechanism for viral 
suppression by nanoART. This includes altered expression of endosomal proteins 
resulting in parallel reductions in viral assembly sites. In addition, reduction of LAMP1 
following nanoART treatment could reduce degradation of the nanoparticles and 
therefore extend the half-life of ART. Our data is corroborated by studies demonstrating 
co-localization of HIV-1 and endosomal and lysosomal proteins (Rab7 and LAMP1) [81, 
167, 168]. Moreover, differences in cytokine profile expressions in untreated and 
nanoATV treated infected HIV-1 macrophages suggest that nanoATV down regulated 
the expression of pro-inflammatory cytokines. HIV-1 has been linked to the up-regulation 
of cytokines and in fact HIV-1 Tat upregulates IL-12 and TNF-α and -β expression in 
monocyte-derived dendritic cells [169, 170], suggesting an advantage of nanoATV in the 
regulation of pro-inflammatory cytokines during HIV-1 infection. In contrast with 
nanoATV, the effect of native ATV was relatively lower. Moreover, it has been reported 
that IL-12 up-regulates Rab7 and induces lysosomal transport. Others have reported 
that Rab proteins are regulated by cytokines and affect TNF secretion by activated 
macrophages [171-173]. These findings provide further support to link Rab, IL-12 and 
TNF expression. As HIV-1 virions assemble at the plasma membrane and recruit 
endosomes to enable particle release, nanoATV depletes endosomal/lysosomal proteins 
and deregulates pro-inflammatory cytokines thus controlling viral growth. Although a 
mechanism is now forged to bridge nanoATV activities and endosomal signaling 
pathways this study serves as only an entry to future investigations.  
To this end, we are currently examining the possible signaling pathways 
deregulated by nanoATV. Altogether, we found that SWATH-MS proteomics, 
bioinformatics analyses and cell biology showed that nanoATV treatment of HIV-infected 
MDM can down-regulate the endocytic proteins in HIV-1 infected cells and thus 
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decrease the subcellular space available for viral assembly. Through this mechanism, 
nanoATV has unique but real potential towards improving virus clearance. Our work 
articulates commonly used pathways that are engaged in common macrophage 
functions such as phagocytosis and vesicular trafficking that are used both by the virus 
and the anti-virus. 
4.6. Conclusions 
HIV-1 and nanoATV deregulate cellular proteins in opposing manners. The common 
pathways are linked to viral assembly and are endolysosomal-linked. Rab5, 7, 11 and 
LAMP1 serve to coordinate molecular and biological functions of the virus and the 
antivirus in subcellular compartments. Alterations made by HIV-1 and nanoATV indicate 
that specific organelles are action sites for both. These findings provide novel insights 
into the role played by long acting subcellular targeted nanotherapies for combating HIV-





Figure 4.1. Deregulated proteins during HIV-1 infection and nanoATV treatment.  
Uninfected and HIV-1 infected MDM were treated with or without nanoATV. The cells 
were then collected for peptide identification. (A) Numbers of significantly up- or down- 
regulated proteins were identified by mass-spectrometry based proteomics (SWATH-
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MS) and compared to uninfected and untreated MDM used as controls. (B) Numbers of 
proteins changed by PANTHER were classified according to protein class. These were 




Figure 4.2. Functional characterization of significant deregulated proteins between 
uninfected and HIV-1-infected and nanoATV treated MDM.  
Proteins were compared to uninfected/untreated control cells (p<0.05) then 
bioinformatics analysis was performed. The Gene Ontology molecular function (A), 
biological processes (B) and cellular component distribution (C) were obtained from the 





Figure 4.3. Schematic representation of the MDM phagosome network identified in 
HIV-1-infected (A) and HIV-1-infected and nanoATV treated cells (B).  
Proteins identified were compared against control uninfected MDM cultures (p<0.05). 
The acquired profiles were analyzed through the bioinformatics program using a 
comprehensive set of functional annotation tools to uncover biological data sets behind 
the uncovered list of genes. This tool is titled Data for Annotation, Visualization and 
Integrated Discovery (DAVID) facilitated the linked sets of enriched functional-related 
protein groups. This tool was employed to identify enriched biological processes among 
the expressed proteins. Gene Ontology terms were used to identify related pathways 
with the assistance of the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database. The KEGG database facilitated the elucidation of the level functions for the 
MDM as derived from the proteomic datasets. Statistical significance was determined 
using a p-value < 0.05. Proteins in red and blue, display up- and down- regulation, 







Figure 4.4. Changes in MDM phagosome network for uninfected cells treated 
treated with nanoATV (A) or native ATV (B).  
Proteins were compared to uninfected and untreated MDM controls (p<0.05) then 
bioinformatics analysis performed following parallel procedures described in Figure 4.1. 
Proteins in red and blue, display up- and down- regulation, respectively. Proteins in 
green belong to the phagosome network but were not significantly altered by viral 











Figure 4.6. NanoATV treatment effects HIV-1 reverse transcriptase (RT) activity.  
HIV-1 RT activity was determined in treated (native ATV or nanoATV) MDM followed by 
HIV-1 infection at days 0, 5 or 10. HIV-1 infected cells, without any treatment, served as 
a positive control for RT activity. All samples were collected after 7 days of viral infection. 






Figure 4.7. NanoATV and HIV-1 endosomal protein regulation.  
Western blot of Rab5, -7, -11，LAMP1 and β-actin was performed in cell lysates from 
MDM treated with native ATV or nanoATV and infected with HIV-1 at day 0, 5 or 10 post-
drug treatment then incubated for 7 days. Uninfected cells and infected cells without 
drug treatment served as negative and positive controls for differential expression of 
cellular proteins during HIV-1 infection. Blots shown are from one donor and experiment, 





Figure 4.8. Subcellular localization of nanoATV, HIV-1 and endolysosomal proteins.  
Cellular localization of Rab7 or LAMP1 endosomal compartments [51], HIV-1p24 
(yellow) and nanoATV [174] are shown by confocal microscopy. Cell nuclei were stained 
with DAPI (blue). Merged images showed the co-localization of all proteins. 





Figure 4.9. NanoATV regulation of cytokine profiles in HIV-1 infected MDM.  
MDM were treated with 100 µM native ATV or nanoATV and infected with HIV-1 at day 
0, 5 or 10 post-drug treatment. Untreated, uninfected cells were used as controls. After 
24 hours of viral infection, cell culture media were collected and analyzed using a 
cytokine bead array. (A) Density plots show expression of IL-12, TNF, IL-10, IL-6, IL-1b 
and IL-8 for control, treated, HIV-1 infected and treated infected MDM. Cytokine levels 
were detected by FACSArray cytometer and data was plotted using FlowJo (version 
10.7) software. (B) Levels of IL-12 and TNF after treatment and infection are shown. 
Data are analyzed using FCAP software and values of cytokine expression were 




Table 4.1. Endolysosomal proteins in HIV-1, HIV+nanoATV, nanoATV and native 
ATV treated MDM. 
Deregulated (up- and down- regulated) proteins from the endolysomal (or phagosome) 
pathway were grouped into early or late endosomes or lysosomes signalling. Z test 
values were obtained after proteomics analyses. Up-, down- regulation or unchanged 
protein expression are represented by red, blue and green arrow, respectively.  
          
  
HIV HIV+nanoATV nativeATV nanoATV 
 










Rab5 4.09 ! -2.57 " -2.35 " 2.87 ! 
TAP 3.38 ! -- #$ -- #$ -- #$ 
TfR 2.62 ! -3.02 " -- #$ -- #$ 
vATPase 3.70 ! 2.32 ! -5.21 " -2.02 " 
Stx13 -- #$ 3.47 ! -- #$ -2.43 " 
EEA1 -- #$ -- #$ 2.62 ! -- #$ 
VPS34 -- #$ -- #$ -- #$ -- #$ 
CALR -- #$ 2.03 ! 2.29 ! -3.73 " 









Rab7 2.71 ! -2.62 " 3.87 ! -- #$ 
vATPase 3.70 ! 2.30 ! -5.20 " -2.02 " 
Dynein -2.01 " -- #$ -- #$ -- #$ 
TUBB -2.90 " 2.81 ! -- #$ -- #$ 
TUBA -- #$ -- #$ -- #$ -- #$ 
RILP -- #$ -- #$ -- #$ -- #$ 







LAMP 2.88 ! -2.23 " -- #$ -- #$ 
vATPase 3.70 ! 2.30 ! -5.20 " -2.02 " 
TAP 3.40 ! -- #$ -- #$ -- #$ 
M6PR -- #$ -- #$ -- #$ -- #$ 
Cathepsin -- #$ -- #$ -- #$ -- #$ 
          
  







Chapter V.  
Small magnetite antiretroviral 
therapeutic nanoparticle probes 
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5.1. Abstract 
Drug toxicities, patient compliance and limited penetrance into viral reservoirs have 
diminished the efficacy of long-term antiretroviral therapy (ART) for treatment of human 
immunodeficiency viral (HIV) infection. In response, cell targeted nanoformulated ART 
(nanoART) was developed to facilitate drug adherence and improve disease outcomes. 
However, rapid noninvasive determination of drug biodistribution in virus-target tissues 
and reservoirs for nanoART have remained unrealized. To this end, small magnetite 
ART (SMART) particles were made providing, for the first time, noninvasive 
assessments of antiretroviral drug tissue distribution through magnetic resonance 
imaging (MRI) techniques. Here, poly(lactic-co-glycolic acid), 1,2-distearoyl-sn-glycero-
3-phosphocholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-2000] encased particles were synthesized that contained 
atazanavir (ATV) and ultra small paramagnetic iron oxide (referred to as magnetite). 
Cellular uptake and retention of magnetite and ATV were first performed in human 
monocyte-derived macrophages (MDM). Here tandem mass spectrometry showed that 
SMART particles were efficiently taken up and retained in MDM. In mice, magnetite and 
drug biodistribution paralleled one another, as readily seen after parenteral injections. 
Three to one ratio of ATV to magnetite allowed drug assessments, for proof of concept 
experiments, continuously up to 4 and again at 24 hours after particle injection. T2 maps 
and 3D spoiled gradient recalled echo image sets confirmed rapid drug tissue 
distribution in the reticuloendothelial system including spleen, liver, kidney and lung.  At 
four hours, T2 mapping showed predominant vascular particle distribution. However, by 
24 hours signal intensity was seen in liver and spleen with little to no magnetite in 
kidneys. Significantly, ATV tissue levels correlated with changes in tissue relaxivity 
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(DR2=1/T2postinjection-1/T2preinjection). We conclude that SMART can facilitate the evaluation 
of drug tissue concentrations in viral reservoirs and provide rapid assessments for the 
next generation cell and tissue ligand decorated particles. 
5.2. Introduction 
Eradication of the human immunodeficiency virus type one (HIV-1) in its infected human 
host will necessitate antiretroviral drug delivery to viral sanctuaries with the secondary 
elimination of latent or restricted infections [75]. The former could be facilitated through 
targeted nanoparticle drug delivery but, to achieve its potential, would require improved 
virus-target tissue drug bioavailability. One major hurdle towards achieving this goal is 
the dearth of any means to measure antiretroviral therapy (ART) distribution outside of 
plasma drug levels [76]. We theorized that one way to achieve this is by combinations of 
small magnetite particles and ART in a single nanoparticle. If realized, such small 
magnetite ART (SMART) could permit rapid pharmacokinetic and pharmacodynamics 
evaluations of ART in virus-target tissues, such as the lymph nodes and brain. Drug 
biodistribution would readily be quantitated by a conventional magnetic resonance 
imaging (MRI) scan. Such an approach would also provide the potential of delivering 
packaged medicines to sites of limited viral growth and serve, in part, to eliminate the 
viral reservoir. The approach was previously used for magnetically targeted cancer drug 
delivery utilizing T2- or T2*-quantification by MRI [175-178].  
To perform proof of concept studies on this theranostic approach we placed magnetite, 
also referred to as superparamagnetic iron oxide particles, into lipid-coated polylactic-co-
glycolic acid (PLGA) nanoparticles with a commonly used antiretroviral protease inhibitor, 
atazanavir (ATV). By combining PLGA and magnetite, organic/inorganic hybrid 
composite biomaterials allowed combined diagnostics, or drug distribution assessments, 
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with therapeutic ART delivery through a single MRI scan [80]. The SMART nanoparticle 
testing was sped through the availability of in vitro cultivated monocyte-derived 
macrophages (MDM) that determined optimal particle cell uptake and retention.  This 
facilitated studies of the dynamics of in vivo drug tissue distribution. All together, the 
works provide the groundwork for the implementation of SMART systems for 
noninvasive drug pharmacokinetics for the inevitable goal of viral eradication. 
5.3. Materials and methods 
5.3.1. Material preparation and characterization 
PLGA, 1,2-distearoyl-sn-glycero-3-phospho-choline (DSPC) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-
PEG2000) encased the SMART particle containing ATV and magnetite. The magnetite 
particles were synthesized as follows: 6 mmol tris(acetylacetonato) iron(III) was mixed 
with 30 mmol 1,2-hexadecanediol, 18 mmol oleic acid, 18 mmol olylamine and 60 mL 
benzyl ether in a three-neck round-bottomed flask equipped with condenser, magnetic 
stirrer, thermograph and heating mantle and stirred under nitrogen. The mixture was 
slowly heated to 110oC and kept at that temperature for 1 hour, then slowly heated to 
200oC. Reflux was kept after it reached 200oC for 2 hours, then slowly heated to 298oC 
and kept at reflux for another 1.5 hours. After cooling to room temperature, a dark 
homogeneous colloidal suspension was obtained. The suspension was precipitated in 
ethanol with a magnetic field. The black precipitate was dissolved in hexane with the 
presence of oleic acid and oleylamine and the solution was centrifuged at 3,800 x g for 
10 min to remove any undispersed residue. The black solution was re-precipitated in 
ethanol and centrifuged at 10,000 x g for 30 min. Solid products were obtained by drying 
the precipitate under vacuum, generating the final dry particles. 
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5.3.2. SMART composition and characterization 
Preparation of the drug loaded DSPC/mPEG-DSPE shell and PLGA core particle was as 
follows. First, a weighed amount of PLGA, ATV and magnetite were dissolved in 
chloroform (oil phase) with a weight ratio of magnetite to ATV of 1:3. Second, the 
aqueous phase was prepared by hydration of DSPC and mPEG-DSPE films. The oil 
phase was added to the DSPC and mPEG-DSPE aqueous solution drop-by-drop with 
constant stirring then sonicated for 60 seconds followed by a 20 second break under an 
ice bath. This procedure was repeated for three cycles. Chloroform was then removed 
by stirring overnight. Third, the particle suspension was centrifuged at 500 x g for 5 min.  
The supernatant fluids were collected to remove the aggregated nanoparticles. A high 
speed 50,000 x g centrifugation for 20 min was used to collect the nanoparticles. After 
washing twice with phosphate-buffered saline (PBS), the nanoparticles were 
resuspended. SMART size and size distribution were measured by dynamic light 
scattering (DLS, 90Plus, Brookhaven Instruments Co. USA) then diluted in ultrapure 
water related to mass concentrations and dispersions. Fourth, the surface charge of the 
SMART particles was determined by ZetaPlus, a zeta-potential analyzer (Brookhaven 
Instruments Co. USA). The pH value and concentration of the particles dispersion were 
fixed before measurements of zeta potentials. Fifth, the shape and surface morphology 
of the SMART particles were investigated by transmission electron microscopy 
performed as previously described [63]. Samples were prepared from dilutions in 
distilled water of particle suspensions and dropped onto stubs. After air drying the 
particles were coated with a thin layer of gold then examined by transmission electron 
microscopy. The magnetic properties were determined by a Physical Property 
Measurement System [179]. 
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5.3.3. SMART particle stability and release of drug in isotonic solution  
SMART particles were dispersed in PBS and placed into a 10 k dialysis tube in 2 L PBS 
under stirring at 37oC. At 30 min and 1, 2, 3, 4, 6, 8 and 10 days, 100 ml of the 
suspension was collected. The supernatant was dissolved in 100 µl 
tetrahydrofuran/methanol (volume ratio 1:10) mixture. The amount of ATV and magnetite 
was measured by high performance liquid chromatography (HPLC) and inductively 
coupled plasma mass spectrometry (ICP-MS), respectively [63, 180]. 
5.3.4. SMART uptake and retention by MDM  
Human monocytes were obtained by leukapheresis, from HIV-1 and hepatitis B 
seronegative donors, then purified by counter-current centrifugal elutriation [106]. 
Monocytes were cultured in 6-well plates at a density of 1 x 106 cells/ml in DMEM 
containing 10% heat-inactivated pooled human serum, 1% glutamine, 50 mg/ml 
gentamicin, 10 mg/ml ciprofloxacin and 1,000 U/ml recombinant human macrophage-
colony stimulating factor [57]. After 7 days of differentiation, MDM were treated with 100 
mM SMART particles, (based upon ATV content). Uptake of SMART particles was 
assessed without medium change for 8 hours. Adherent MDM were collected by 
scraping into PBS, at 1, 2, 4 and 8 hours after treatment. Cells were pelleted by 
centrifugation at 1000 x g for 8 min at 4oC. Cell pellets were briefly sonicated in 200 ml of 
methanol/acetonitrile (1:1) and centrifuged at 20,000 x g for 10 min at 4oC. To determine 
cell retention of SMART particles, MDM were exposed to 100 mM SMART particles for 8 
hours, washed 3x with PBS, and fresh media without particles was added. MDM were 
cultured for an additional 15 days with half medium exchanges every other day. On days 
1, 5, 10 and 15 after SMART treatment, MDM were collected as described for cell 
uptake. Cell extracts were stored at -80oC until HPLC analysis [63].  
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5.3.5. Prussian blue staining of MDM retained SMART particles 
 MDM were treated with 100 mM SMART particles for 24 hours. Adherent MDM were 
washed 3x with PBS. Cells were fixed with 2% formalin/2.5% glutaraldehyde in PBS for 
10 min then washed 2x with PBS. Fixed macrophages were treated with 5% potassium 
ferrocyanide/5% hydrochloric acid (1:1) for 10 min at room temperature. Following 
solution aspiration the cells were washed 2x with PBS. Stained cells were examined by 
light microscopy. 
5.3.6. MRI phantoms and relaxivity measures  
MDM were seeded onto 12-well plates at 1 x 106 cells/ml. After the cells reached 80% 
confluence, the medium was changed to medium containing 100 mM SMART particles 
(based on ATV content). Twenty-four hours later the treatment medium was removed 
and the cells were washed 3x with 1 ml PBS. Cells were collected and suspended at 
different cell concentrations (0-5 x 106 cells/ml) in 1% agar gel. T2-relaxtivity was 
measured by MRI. Magnetite content in the cells was quantitated by ICP-MS.   
5.3.7. SMART biodistribution 
Biodistribution of SMART particles was determined in male Balb/cJ mice (Jackson Labs, 
Bar Harbor, ME). SMART particles (30 mg/kg ATV) were injected via a jugular vein 
cannula in a total volume of 100 ml for each mouse. The mice were scanned by MRI two 
hours before injection then continuously at 0.25, 1, 2 and 4 hours or at 24 hours after 
SMART administration. Tissues were collected following the final MRI scan. Tissue drug 
levels were quantitated by ultra performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) [181] and magnetite levels were determined by ICP-MS as 
previously described [180].  
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5.3.8. MRI acquisition 
MRI was acquired using a 7T/16cm Bruker (Ettlingen, Germany) Pharmascan MRI/MRS 
scanner and a commercial mouse body resonator. SMART detection by MRI was done 
using T2 mapping for quantitation and T2* weighted high resolution imaging for detection 
of biodistribution throughout the body. The sequence used for T2 mapping was a CPMG 
phase cycled multislice multiecho sequence. Forty-one 0.5 mm thick contiguous 
interleaved coronal images were acquired with an acquisition matrix of 256 x 192, 40 
mm field of view, 12 echoes at 10 ms first echo time and 10 ms echo spacing, repetition 
time of 4680 ms, three averages, for a total acquisition time of 30 min.  T2* weighted MRI 
was acquired using a 3D spoiled gradient recalled echo sequence with echo time = 3 ms, 
repetition time = 10 ms, 15 degree pulse angle, 50 x 40 x 30 mm FOV, 256 x 196 x 128 
acquisition matrix, six averages, for a total scan time of 25min.  
5.3.9. MRI analyses 
T2 maps were reconstructed using custom programs written in Interactive Data 
Language (IDL; Exelis Visual Information Solutions, McLean, VA). Preinjection and 24 
hour postinjection maps were constructed using the even-echo images from the CPMG 
phase cycled imaging data set. Mean tissue T2 was determined using region of interest 
[164] analyses before and after SMART injection for the 24 hour results. Magnetite 
concentration was then determined from the change in relaxivity (DR2 = 1/T2preinjection - 
1/T2postinjection) and the per milligram magnetite of SMART particle relaxivity (r2) 
determined as the slope of magnetite concentration versus R2 in phantom studies.  
Acute (0-4 hour) data were acquired with in-magnet jugular vein injection, allowing 
sequential T2 mapping to be acquired with a T2* weighted FLASH image acquired at the 
end of a four-hour period. The natural coregistration of these data allowed development 
of magnetite concentration maps based on relaxivity changes using custom programs 
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written in IDL for the acute scanning session. The ROI analyses were performed using 
ImageJ (http://imagej.nih.gov/lj) software. For analysis of the acute study, the windows 
synchronize option was used to simultaneously draw ROIs at same locations on all 
concentration maps at different time points. 
5.3.10. Immunohistochemical identification of cell-SMART uptake 
To determine cell localization of SMART spleen and liver were collected after the final 
MRI scan and fixed in 10% neutral buffered formalin. Tissues were paraffin embedded 
and sectioned at 5 µm. To identify macrophages, sections were incubated with antibody 
to ionized calcium binding adaptor molecule 1 (Iba1, Wako Chemicals USA, Inc., 
Richmond, VA). The polymer-based HRP-conjugated anti-mouse and anti-rabbit Dako 
EnVision were used as secondary detection reagents and color developed with 3,3'-
diaminobenzidine (DAB). All paraffin-embedded sections were stained with Prussian 
blue to identify magnetite content.  Slides were imaged using a Nuance light microscopy 
system for brightfield imaging. 
5.4. Results and discussion  
5.4.1. SMART development and in vitro evaluation  
The schematic structure of SMART is represented in Figure. 5.1A. This is composed of a 
hydrophobic PLGA/ATV/magnetite core and an amphiphilic DSPC and DSPE-PEG2k 
lipid shell. DSPC and DSPE-PEG2k increased SMART stability and facilitated increased 
systemic formulation circulation times. Both ATV and magnetite are distributed 
homogeneously within the core of the particle. SMART was made using a single oil-in-
water emulsion with lipid surfactants. After sonication amphiphilic lipids self-assembled 
to the monolayer surrounding PLGA/ATV/magnetite containing oil droplets, achieved 
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through hydrophobic interactions. Evaporation of chloroform under continuous magnetic 
stirring allowed for the formation of lipid-coated solid PLGA/ATV/magnetite core. SMART 
was then purified by ultracentrifugation before further characterization. Our DLS results 
showed that the average size of the particles is 268 nm with a polydispersity of 0.2. The 
narrow size distribution is linked to the DSPC, which serves to stabilize the polymeric 
SMART in the aqueous phase. The zeta potential of the particles is -45.2 mV, which 
provides its stability when suspended in aqueous media. Although DSPC is neutral when 
it is used as a particle coat it exhibits non-zero mobilities in an external electric field. This 
may result in a higher negative charge since some anions bind to the neutral lipids 
making the surface more negatively charged. Transmission electron microscopy (TEM) 
was employed to obtain the image that best reflects SMART particle morphology 
(Figure. 5.1B, right panel). This illustrated that the particles were spherical in shape with 
narrow size distributions. A representative particle is shown by TEM, showing the ultra 
small iron oxide contained within the particle’s core.  
Our preliminary in vitro results showed that SMART is very stable and ATV can slowly 
release from SMART up to 10 days. After SMART particle characterizations were 
completed, the in vitro kinetics of MDM uptake and retention were determined. Our 
previous studies of nanoART uptake in MDM showed that > 95% of total uptake occurs 
by 8 hours for ATV nanoART [62, 63, 82, 182]. Up to 2 mg of ATV/ 106 cells was 
recorded in MDM at 8 hours with magnetite uptake reflective of particle composition 
(Figure. 5.1C). The majority of the cells took up the magnetite as observed through 
Prussian blue staining (Figure. 5.1D). Indeed, such staining demonstrated that 
magnetite-containing particles were readily incorporated in macrophages by 8 hours. 
The controlled and sustained release profile or ATV facilitates the application of the 
SMART particles for the delivery of antiretroviral drugs.  
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5.4.2. Measures of SMART particle relaxivity (r2)  
Concentration dependent relaxivity [r2 (s-1 ml mg-1)] causing increased relaxivity (R2 (s-1)) 
in tissue as a function of concentration (expressed as mg/ml magnetite) of SMART 
particles were determined using phantoms consisting of both free SMART particles 
(Figure. 5.2A) and SMART particles taken up by MDM (Figure. 5.2B). The magnetite 
concentrations in mg/ml contained by SMART in 1% agar gels were plotted against R2 
as measured by MRI. The relationship between R2 and magnetite concentration of 
SMART in phantoms was linear within the range of the measured magnetite 
concentrations. The concentration dependent relaxivity of SMART was found to be r2 = 
6200.2 (s-1 ml mg-1) in MDM and r2 = 7052.1 (s-1 ml mg-1) in PBS. The r2 of SMART in 
MDM was used for noninvasive in vivo quantitation of magnetite concentration due to 
SMART influx using MRI.    
5.4.3. Real time SMART biodistribution and pharmacokinetics 
Magnetite labeling allows MRI to be used to quantify the distribution of SMART particles 
over time in live animals. This can be seen in Figure. 5.3. Figure. 5.3A shows examples 
of magnetite concentration (from magnetite in SMART) constructed from MRI T2 maps 
measured before and continuously every 30 minutes for four hours after SMART 
injection. ROI analyses of these data from six animals are shown in Figure. 5.3B. It can 
be appreciated from the images that a significant amount of the SMART is still within the 
vasculature, largely leading to the intensity in the kidney, as kidney shows very little 
uptake by 24 hours. This reflects the measured concentration in kidney reducing over 
the first four hours while in liver and spleen, organs where SMART accumulates, the 
mean signal is relatively constant or increases as the particles redistribute from the 
blood to the tissue. Significant accumulation of SMART was found in liver and spleen at 
4 hours as can be appreciated in Figure. 5.4. Figure. 5.4 displays two of the 0.128 mm 
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thick T2* weighted high resolution 3D FLASH images of the same mouse before and 4 
hours after injection of SMART. Presence of magnetite in tissue causes a reduction of 
T2* to the point of complete signal loss at TE = 3 ms in the liver, spleen, and some 
abdominal regions. This method is not quantitative, however it does allow ready 
identification of the presence of magnetite throughout the body which can be used to 
guide quantitative ROI analyses using T2 maps. 
5.4.4. Correlation between magnetite and drug tissue content 
Figure. 5.5 shows the relationship between magnetite concentration and ATV 
concentration of liver, spleen and kidney in four animals 24 hours after injection. It can 
be appreciated that there is a significant positive correlation (Pearson Correlation, 
r=0.786, p=0.0008). These results demonstrate the capability of MRI to be used for 
monitoring nanoART distribution. 
5.4.5. Identification of magnetite-ART relationships in systemic tissues 
We reasoned that cellular biodistribution of SMART was concordant with our prior results 
with nanoART [183]. To prove this theory we next studied the relationships between 
SMART particle biodistribution and macrophages in mice following parenteral SMART 
injections. Animals were sacrificed 4 hours after injection and tissues collected. Dual Iba-
1 (for macrophages) and Prussian blue staining (for magnetite) were performed and 
evaluated by brightfield microscopic imaging. Prussian blue staining was nearly 
exclusively in tissue cells identified as macrophages. As shown in Figure. 5.6, Iba-1+ 
macrophages were readily seen in both liver and spleen in parallel to distribution of 
Prussian blue. The dual staining pictures showed that the SMART particles were 
retained in tissue macrophages. Erythrocyte hemoglobin and its breakdown products are 
a substantive source of iron. These are degraded after the lifespan of the erythrocyte 
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[38]. This occurs predominantly in the spleen with iron transferred back into the blood. 
The highly vascularized spleen contains easily seen red blood cell breakdown products 
including iron that are phagocytized by macrophages [34]. Thus, the total iron content in 
the spleen is readily visualized by Prussian blue staining but substantively increased 
after SMART treatments (Figure. 5.6G and H). The iron content in spleen also changed 
from 228 µg/g before treatment to 356 µg/g after treatment, measured by ICP-MS. This 
also explains why background MRI scans are darkened in the spleen but increased after 
injection of SMART particles. 
5.5. Discussion  
Our laboratories are responsible for the development of cell-based carriage and delivery 
of antiretroviral drugs to sites of active HIV-1 replication [63, 82, 95, 106, 182, 184, 185].  
This so-called “Trojan Horse” macrophage drug delivery scheme takes full advantage of 
the cells’ substantive endosomal storage capacity, its phagocytic and secretory functions, 
and its high degree of mobility to facilitate drug delivery [81]. As the macrophage is a 
principal cell target for viral growth, the added benefit rests in the abilities to bring ART to 
subcellular sites of viral assembly [186]. Such a system when used as a weekly or 
monthly parenteral injection has previously been shown to hold significant gains over 
conventional native oral drug therapeutic regimens [184, 185].  
The principal goal in developing this polymer system rests in the ability to utilize MRI 
scans to rapidly assess cell and tissue drug biodistribution.  The idea is that the polymer-
encased dual magnetite and drug particle would permit a clear determination of drug 
levels in virus-target tissues in a very short time interval (hours).  As plasma drug levels 
remain the gold standard for pharmacokinetic testing this technology clearly opens new 
opportunities to develop platforms that would accelerate elimination, or some day cure, 
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of viral infections. Notably, there is a considerable focus amongst HIV/AIDS researchers 
towards the development of any or all reliable methods to bring drugs to reservoir sites 
with the explicit goal of eliminating virus.  Targeted drug as well as gene delivery when 
combined with suitable imaging techniques could facilitate this goal by providing a “go/no 
go” for treatment success [63]. Although this is the first time such “theranostics” has 
been applied for HIV diagnosis and therapies, similar systems have been developed in 
recent years for cancer treatments [187]. Here, the application is for early diagnostics. 
The unique payloads of nanomaterials include fluorescent semiconductor nanocrystals 
(quantum dots) as well as magnetic nanoparticles as developed in this report.  All 
provide properties that can facilitate in vivo imaging with the help of MRI tests as well as 
fluorescence based approaches [188]. In all, interest in this idea will likely continue to 
grow through the development of carrier nanoparticles designed to target specific tissue 
and effect local chemo-, radio- and gene- directed antiretroviral or immune modulatory 
therapies [189]. 
Liposomes and polymer nanoparticles are the two major types of nanoparticles that have 
been developed and evaluated for diagnostic and therapeutic purposes. Liposomes 
composed of natural lipids are attractive DDS because of their high biocompatibility, low 
immunogenicity, long systemic circulation and favorable pharmacokinetic profile. 
Specific targeted delivery can easily be achieved by conjugating a targeting ligand to the 
lipid molecule [190-192]. Several liposomal drug formulations have been approved by 
FDA for clinical application, such as Doxil and DaunoXome [190, 192, 193]. However, 
the possible intrinsic low drug loading capacity, fast release profiles of hydrophobic 
drugs and physical instability of liposomes limit their clinical applications of different 
drugs [194]. Polymeric nanoparticles composed of synthetic PLGA are another widely 
developed/studied drug delivery platform because of their high stability, relatively high 
drug loading capacity of all kinds of drugs, biodegradability, low toxicity, and 
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controlled/sustained drug release profiles. Depending on particle composition, the drug 
release profiles of PLGA nanoparticles can be modulated to be within days, weeks or 
even months [195-197].  However, the biocompatibility/immunogenicity of nanoparticles 
composed of synthetic polymers including PLGA is not as high as liposomes. Without 
further chemical modification, PLGA nanoparticles are rapidly removed from circulation 
by the mononuclear phagocyte system (MPS), resulting in short systemic circulation 
[194]. In summary, both liposomes and PLGA nanoparticles are not independently 
structurally robust platforms. Thus, lipid-coated polymer nanoparticles, formed by 
combining synthetic polymers and natural lipids, have been developed as robust drug 
delivery platform to combine the advantages and avoid the disadvantages of liposomes 
and polymer nanoparticles [198, 199].  
The visualization of cellular function in living organisms is not a new modality [106, 200, 
201]. Optical, X-ray, nuclear, MRI and ultrasound allows three-dimensional whole-body 
scans at high spatial resolution and are adept at morphological and functional 
evaluations. The data obtained can be enhanced by magnetite and improved image 
resolution. By immobilizing a specific target molecule on the surface of a magnetic 
particle, the molecule inherits its magnetic property. Magnetic tissue targeting using 
multifunctional carrier particles can also facilitate effective treatments by enabling site-
directed therapeutic outcomes. To this end, we selected DSPC and DSPE-PEG2k as the 
shell and PLGA as the core of SMART system. DSPC is used to increase the 
biocompatibility of SMART, and DSPE-PEG2k is used to build a sterically repulsive 
shield around SMART that reduces opsonization, prevents interactions with the MPS, 
escape renal exclusion, and increases systemic circulation. To the best of our 
knowledge, this is the first attempt to develop lipid-coated PLGA nanoparticles for HIV 
therapeutics. Our current work sought to use lipid coated PLGA SMART to encase 
magnetite and antiretroviral therapy to facilitate MDM uptake of drug and its subsequent 
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slow release. The long-term goals are straightforward. One is to use the synthesized 
SMART to facilitate drug screening for specific targeting ligands or sugars.  The second 
is to determine the distribution of nanoART in viral reservoirs for the ultimate eradication 
of HIV. Our in vivo MRI results clearly demonstrated that SMART could facilitate the 
noninvasive evaluation of drug pharmacokinetics and biodistribution in different tissues, 
and provide rapid assessments for the next generation cell and tissue ligand decorated 
particles. This initial study lays the groundwork for what will quickly follow and ultimately, 
we believe, lead to an effective means to combat and potentially eliminate HIV disease.  
 5.6. Conclusions 
We posit that SMART particles can be developed for noninvasive evaluation of drug 
distribution and pharmacokinetics.  These particles show clear potential in allowing a 
rapid evaluation of ART content in viral reservoirs that include the brain and lymphoid 
tissues.  Improve in particle delivery have been seen in cell and tissue targeted particles 




Figure 5.1. Development of SMART nanoparticles.  
(A) The schematic structure of lipid-coated PLGA SMART. ATV and SPIO are well 
distributed within the PLGA matrix to form the core of SMART. The PLGA core is coated 
with lipid monolayer to form the shell of SMART. (B) Representative transmission 
electron micrograph (TEM) of a single SMART particle. (C) Timecourse of uptake (upper 
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panel) and retention (lower panel) of SMART in MDM., MDM were treated with 100 mM 
SMART (based on ATV content) for 1, 2, 4 and 8 hour uptake studies. For cell retention 
MDM were treated with 100 mM SMART for 8 hours, cell culture media was changed 
and cells were cultured for an additional 15 days. The cell lysates at indicated times 
were analyzed by HPLC and ICP-MS for ATV and magnetite quantification, respectively. 
Data represent the mean ± SEM, n = 3, for each time point. (D) Prussian blue staining of 
MDM. MDM were treated with PBS (negative control, upper panel) or 100 mM SMART 
(lower panel) for 24hours, and then fixed with 2% formalin/2.5% glutaraldehyde and 




Figure 5.2. Concentration dependence of relaxivity (r2) of SMART in (A) PBS and 
(B) MDM.  
MDM were incubated with 100 µM SMART (based on ATV content) for 24 hours. 
Collected MDM and SMART were suspended in 1% agar gel. T2 was measured by MRI 




Figure 5.3. MRI assessments of the tissue drug biodistribution and 
pharmocokinetics by SMART particles.  
After pre-MRI scan, mice were injected with SMART through a jugular vein cannula, and 
then scanned by MRI at continuously at 30 minute intervals up to 4 hours after SMART 
administration. Mean tissue SMART content was determined as detailed in Materials 
and Methods. Immediately after the final scan, mice were euthanized and tissues were 
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collected for ATV quantification by UPLC-MS/MS. (A) MRI based images of magnetite 
concentration in kidney, spleen and liver from 0.5 h to 4 h following SMART 
administration. (B) Mean ± SEM (n=6) of magnetite levels in kidney, spleen and liver 





Figure 5.4. 3D gradient recalled echo images of the same mouse before (A) and 4 
hours after (B) injection of SMART.  
It can be appreciated that the signal from the liver is completely eliminated due to the 




Figure 5.5. Correlation of SMART-associated magnetite and ATV in tissues 24 
hours after administration.  
The magnetite concentration was quantified from the change in T2 weighted relaxivity 
(DR2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite relaxivity (r2) 
determined as the slope of magnetite concentration versus R2 in SMART phantom 







Figure 5.6. Immunohistology of Iba-1 staining and Prussian blue staining. 
(A) Liver from control mice with Prussian blue (200×). (B) Liver from SMART treated 
mice with Prussian blue (200×). (C) Liver from SMART treated mice with Prussian blue 
and Iba-1 (200×). (D) Enlargement from indicated section in C. (E) Spleen from SMART 
treated mice with Prussian blue (200×). (F) Spleen from SMART treated mice with 
Prussian blue and Iba-1 (200×). (G) Enlargement from indicated section in F. (H)  Spleen 
from control mice with Prussian blue and Iba-1 (400×). Livers and spleens were fixed 
with 10% formalin, paraffin embedded and sectioned for immunohistological analysis 
after the final MRI scan. Macrophages were identified by Iba1 stains (brown) and 










Chapter VI.  





Our laboratory has developed nanoART for improved formulation stability and 
bioavailability, higher intracellular drug concentrations, and sustained in vivo drug 
release. It has realized long-acting antiretroviral therapy for types of hydrophobic 
antiretroviral drugs. In this study, we focused on hydrophilic nucleoside reverse 
transcriptase inhibitor—lamivudine. A hydrophobic 3TC prodrug was successfully 
synthesized through myristoylation and incorporated into targeted and non-targeted 
nanocrystalline formulations to improve drug half-life and reduce cytotoxicity. NMTC 
exhibited enhanced macrophage uptake and sustained antiretroviral efficacy. FA-NMTC 
exhibited improved pharmacokinetics and this novel drug delivery system has shown 
great potential for clinical application. In our subcellular trafficking study, we found 
macrophages could act as carriers of nanoART to improve drug bioavailability. Late and 
recycling endosomes are depots for both drug particle and HIV, and nanoATV and HIV-1 
utilize similar subcellular pathways. SWATH-MS profiling broad the understanding of 
complex nanoART-HIV interactions. HIV-1 and nanoART deregulate cellular proteins in 
opposing manners and specific organelles are action sites for both. Rab5, 7, 11 and 
LAMP1 serve to coordinate molecular and biological functions of HIV-1 and drug 
particles. Besides, we developed SMART particles for noninvasive evaluation of drug 
distribution and pharmacokinetics. These studies unveil a broader understanding of 
nanomedicine for antiretroviral therapy and exhibit great potential in its future clinical 
applications.  
Overall, this project has exhibited the great potential of our nanoformulated antiretroviral 
drug delivery system in the clinical applications. In the future, all types of antiretroviral 
drugs can take advantage of this system for improved antiretroviral efficacy and 
pharmacokinetics. Besides folic acid, different targeting ligands will be developed and 
utilized for nanoformulation development, which will uncover new mechanisms for long-
acting antiretroviral therapy.  
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